[
  {
    "id": "1f14333d-0ac5-47cc-b44e-c0c5c9a609d2",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer",
    "abstract": "In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients.",
    "published": "2025-12-18",
    "authors": [
      "Thomas Powles, Ariel G. Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Sergio Bracarda, Jørgen Bjerggaard Jensen, Lydia Makaroff, Shusuan Jiang, Ja Hyeon Ku, Se Hoon Park, Oscar Reig Torras, Dingwei Ye, Marco Maruzzo, Andrea Necchi, Rafael Morales-Barrera, Emilio Francesco Giunta, Jae Lyun Lee, Giampaolo Tortora, Yüksel Ürün, Lukasz Dolowy, Dilek Erdem, Alvaro Pinto, Fabricio Grando, Wei Zou, Zoe June Assaf, Jacqueline Vuky, Viraj Degaonkar, Elizabeth E. Steinberg, Joaquim Bellmunt, Jürgen E. Gschwend, the IMvigor011 Investigators*"
    ],
    "doi": "10.1056/NEJMoa2511885",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2511885?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "346d1446-807c-4cfc-8d1b-b2f623e02180",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Noninferiority of One HPV Vaccine Dose to Two Doses",
    "abstract": "In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.",
    "published": "2025-12-18",
    "authors": [
      "Aimée R. Kreimer, Carolina Porras, Danping Liu, Allan Hildesheim, Loretto J. Carvajal, Rebeca Ocampo, Byron Romero, Mitchell H. Gail, Bernal Cortes, Monica S. Sierra, Karla Coronado, Joshua Sampson, Carolina Coto, Casey L. Dagnall, Daniela Mora, Troy J. Kemp, Michael Zuniga, Ligia A. Pinto, Gloriana Barrientos, John Schussler, Yenory Estrada, Cristian Montero, Carlos Avila, Dave Ruggieri, Jean T. Cyr, Stephen Chanock, Douglas R. Lowy, John T. Schiller, Rolando Herrero"
    ],
    "doi": "10.1056/NEJMoa2506765",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2506765?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "afbb65b1-bb59-4e4a-9524-0b5a62cd3d0c",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection",
    "abstract": "Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...",
    "published": "2025-12-18",
    "authors": [
      "Ruanne V. Barnabas"
    ],
    "doi": "10.1056/NEJMe2515387",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2515387?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e5d85ced-eafa-4c7f-8934-060314e0194c",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Reducing Tobacco Use Worldwide: The Epidemic of Tobacco Harms among People with Mental Health Conditions",
    "abstract": "High rates of tobacco use among people with mental health conditions contribute to their increased morbidity and mortality, but tobacco cessation interventions can be effective in this population.",
    "published": "2025-12-18",
    "authors": [
      "Simon Gilbody, Garima Bhatt, Krishna P. Muliyala"
    ],
    "doi": "10.1056/NEJMp2500491",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMp2500491?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e751428e-da81-4293-936b-92dafab5c1fa",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Merkel-Cell Carcinoma",
    "abstract": "A 72-year-old woman presented with a 3.5-month history of an enlarging, painless lump on her cheek. Examination showed a dome-shaped, reddish nodule on the left cheek, with a shiny surface and central hemorrhagic crust.",
    "published": "2025-12-18",
    "authors": [
      "Zunaid Ahmed, Willem Visser"
    ],
    "doi": "10.1056/NEJMicm2513302",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMicm2513302?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1d26b14d-001b-4393-98aa-a48bd70f3191",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "ctDNA-Guided Therapy in Bladder Cancer — Ready?",
    "abstract": "Liquid-biopsy analysis for circulating tumor DNA (ctDNA) has the potential to transform cancer care through personalized, noninvasive disease monitoring. In bladder cancer, ctDNA is a strong prognostic biomarker after cystectomy and may guide adjuvant treatment decisions. Retrospective and prospective studies show that ctDNA positivity is linked to an increased risk...",
    "published": "2025-12-18",
    "authors": [
      "Lars Dyrskjøt"
    ],
    "doi": "10.1056/NEJMe2514185",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2514185?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "833751a8-c7be-44c5-8bcc-a61387c9fc4e",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer",
    "abstract": "In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy.",
    "published": "2025-12-11",
    "authors": [
      "Xinan Sheng, Gongqian Zeng, Cuijian Zhang, Qingyun Zhang, Jiasheng Bian, Haitao Niu, Jun Li, Yanxia Shi, Kai Yao, Bin Hu, Ziling Liu, Hong Liao, Zhixian Yu, Baiye Jin, Peng Zhao, Tiejun Yang, Xianling Liu, Yang Qin, Xueyi Xue, Xin Gou, Jian Huang, Jiang Gu, Xiaolong Qi, Lu Zhang, Guoxian Ma, Beisong Liu, Jianmin Fang, Shusuan Jiang, Zhisong He, Aiping Zhou, Jun Guo, the RC48-C016 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2511648",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2511648?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "6d7dfd86-bb91-4ee7-a9b9-6837dd10f513",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Understanding How Aspirin Prevents Metastasis",
    "abstract": "A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.",
    "published": "2025-12-11",
    "authors": [
      "Ruth E. Langley, John Burn"
    ],
    "doi": "10.1056/NEJMcibr2502386",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMcibr2502386?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "95f924cd-cd9e-46cd-b725-ae18c094ffff",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Disitamab Vedotin plus Toripalimab — New Players in Urothelial Carcinoma",
    "abstract": "For decades, platinum-based chemotherapy was the standard first-line treatment for locally advanced or metastatic urothelial carcinoma.1 However, the treatment landscape in urothelial carcinoma has shifted with the advent of immune checkpoint inhibitors.2 Although immune checkpoint inhibitors were initially used as single agents after chemotherapy failure, combinations...",
    "published": "2025-12-11",
    "authors": [
      "Jens Bedke"
    ],
    "doi": "10.1056/NEJMe2514668",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2514668?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7a6a57a7-55b7-4f37-9012-9ddd302893e5",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events",
    "abstract": "In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared.",
    "published": "2025-12-11",
    "authors": [
      "Yuxuan Wang, Howard L. Li, Chetan Bettegowda, Kenneth W. Kinzler, Nickolas Papadopoulos, Mark Yarchoan, Bert Vogelstein"
    ],
    "doi": "10.1056/NEJMc2513984",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMc2513984?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f929228b-abe6-4eec-a6da-d67fbde6f286",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer",
    "abstract": "In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease.",
    "published": "2025-12-10",
    "authors": [
      "Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Cui-zhi Geng, Wuilbert Rodriguez Pantigoso, Francisco Javier Ramírez Godinez, Chuangui Song, Yuan Ching Chang, Augusto Antoniazzi, Shin-Cheh Chen, Zhigao Li, Zbigniew Nowecki, Joline Lim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Michael Untch, Charles E. Geyer Jr., the DESTINY-Breast05 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514661",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514661?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f8c12b85-404c-4db3-910b-96d5108621cf",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Ianalumab plus Eltrombopag in Immune Thrombocytopenia",
    "abstract": "In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo.",
    "published": "2025-12-09",
    "authors": [
      "Adam Cuker, Thomas Stauch, Nichola Cooper, Hanny Al-Samkari, Marc Michel, Waleed Ghanima, Patrick Urban, Justyna Fronczek, Matthew Foster, Marine Weill, Lei Zhang, Ming Hou, Thomas Zander, Azizan Sharif, Jing Sun, Uttam Kumar Nath, Roger Schutgens, Elena Rossi, Lien Deleu, Libor Červinek, Jae-Ho Yoon, Hung Chang, Theera Ruchutrakool, Masaki Iino, Tatsunori Goto, Francesco Zaja, the VAYHIT2 Investigators*"
    ],
    "doi": "10.1056/NEJMoa2515168",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2515168?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d3b3f8a2-fcfc-42ab-a10c-9d1a7956ab98",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma",
    "abstract": "In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and had higher response rates.",
    "published": "2025-12-09",
    "authors": [
      "Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A. Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang Ki Min, Paul Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O’Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Maria Victoria Mateos, the MajesTEC-3 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514663",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514663?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7d51a514-856b-4b09-94d2-cae9566da129",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia",
    "abstract": "In relapsed or refractory T-cell acute lymphoblastic leukemia, off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in 11 patients, enabling stem-cell transplantation in 9 patients in deep remission.",
    "published": "2025-12-08",
    "authors": [
      "Robert Chiesa, Christos Georgiadis, Hebatalla Rashed, Roland Preece, Prudence Hardefeldt, Jan Chu, Jemma Selvage, Avijeet Mishra, Batoul Ahmed, Stuart Adams, Rebecca Thomas, Kimberly Gilmour, Annie Etuk, Deborah Yallop, David O’Connor, Waseem Qasim, the Base-Edited CAR T Group*"
    ],
    "doi": "10.1056/NEJMoa2505478",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2505478?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8aba8e31-4958-438f-99f8-838d8ef0a630",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B",
    "abstract": "Among men with hemophilia B, sustained endogenous factor IX expression and low annualized bleeding rates over the course of 5 years were seen after an infusion of etranacogene dezaparvovec.",
    "published": "2025-12-07",
    "authors": [
      "Steven W. Pipe, Wolfgang Miesbach, Michael Recht, Frank W.G. Leebeek, Nigel S. Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra Le Quellec, Vaibhav Mahajan, Sean Gill, Douglass Drelich, Paul E. Monahan, the HOPE-B Study Group Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514332",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514332?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b5671a26-da1f-4e07-97ea-0bf8c5d960de",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab",
    "abstract": "In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common.",
    "published": "2025-12-07",
    "authors": [
      "Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, Yael C. Cohen, the RedirecTT-1 Investigators Study Group*"
    ],
    "doi": "10.1056/NEJMoa2514752",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514752?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "dc652c42-0472-4e78-a242-febc12ee9c1e",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Brief Report: Prime Editing for p47phox-Deficient Chronic Granulomatous Disease",
    "abstract": "In this study, gene editing with a prime editor was used to treat two persons with chronic granulomatous disease caused by a small deletion in the gene NCF1.",
    "published": "2025-12-07",
    "authors": [
      "Jennifer L. Gori, Elie Haddad, Haydar Frangoul, Donald B. Kohn, Emma C. Morris, Bradley N. Martin, Briana A. Deary, McKinley Nickerson, Rebecca L. Scholz, Isabel Fernandez, Karine Leveille, Suk See De Ravin, Elizabeth M. Kang, Marie Pierzynski, Tyra Estwick, Patricia Littel, Douglas B. Kuhns, Debra A. Long Priel, Pierre Teira, Stuart Turvey, Jordyn Arnold, Misty D. Evans, Meghann McManus, Ben Carpenter, David P. Waterman, Andrew V. Anzalone, Alexandria Petrusich, Christa E. Osuna, Tiernan T. O’Malley, Jacob Stewart-Ornstein, Jack M. Heath, Barrett J. Nehilla, Mohammed Asmal, Harry L. Malech"
    ],
    "doi": "10.1056/NEJMoa2509807",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2509807?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b7307632-d7a0-4c22-81bb-fbe459db5f92",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia",
    "abstract": "In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates.",
    "published": "2025-12-06",
    "authors": [
      "Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon P. Kater, Vesa Lindström, Mattias Mattsson, Carsten U. Niemann, Philipp B. Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian B. Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Anna Maria Frustaci, Lydia Scarfò, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek, the CLL17 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2515458",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2515458?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "a733d413-0adb-4677-95ce-645eaf620fdc",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia",
    "abstract": "In patients with hereditary hemorrhagic telangiectasia, treatment with engasertib reduced nosebleed frequency and duration over 12 weeks, with mild reversible rash as the most common drug-related side effect.",
    "published": "2025-11-27",
    "authors": [
      "Hanny Al-Samkari, Josefien Hessels, Antoni Riera-Mestre, Sophie Dupuis-Girod, Thibaut Van Zele, Vicente Gómez del Olmo, Pamela G. Hodges, Raquel Torres-Iglesias, Roberto Bertè, Pierre Saint-Mezard, Hedvika Lazar, Nicholas Benedict, Debra Barker, Corrado Bernasconi, Damien Picard, Elisabetta Buscarini, Hans-Jurgen Mager"
    ],
    "doi": "10.1056/NEJMoa2504411",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2504411?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4a78d0d6-f8ac-4be6-9bfc-33dd4df43756",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Case 34-2025: A 57-Year-Old Woman with Visual Disturbances and Right-Arm Shaking",
    "abstract": "A 57-year-old woman with a history of subarachnoid hemorrhage was admitted to the hospital because of visual disturbances involving the right visual field, as well as episodes of shaking of the right arm and leg. A diagnosis was made.",
    "published": "2025-11-27",
    "authors": [
      "Nancy Wang, Shenghua Zhu, Aman B. Patel, Donald P. Lawrence, Anthony R. Russo"
    ],
    "doi": "10.1056/NEJMcpc2513534",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMcpc2513534?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f250f6ad-db74-4e3d-867d-3b1921e87712",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Editorial] Making prostate cancer screening fit for purpose",
    "abstract": "Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain regarding the best diagnostic pathway. The value of population-based prostate cancer screening using a prostate-specific antigen (PSA) threshold, for example, is long-debated and is not universally recommended because of concerns around the risk of overdiagnosis and overtreatment.",
    "published": "2025-12",
    "authors": [
      "The Lancet Oncology"
    ],
    "doi": "10.1016/S1470-2045(25)00672-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00672-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "dd3d2b12-cb3a-4960-b5b7-e33e3362b1d6",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Defining eligibility for lung cancer screening based on individual risk",
    "abstract": "Implementation of lung cancer screening is advancing globally, and most countries use categorical eligibility criteria resembling those from randomised low-dose CT screening trials. For example, the US Preventive Services Task Force (USPSTF) requires age 50–80 years, at least 20 pack-years smoked, and 15 years or less of cessation. However, beginning in 2013, studies suggested that defining eligibility using individual lung cancer risk prediction models would yield more lung cancer deaths prevented per population screened.",
    "published": "2025-11-10T23:30:01Z",
    "authors": [
      "Hilary A Robbins, Mattias Johansson"
    ],
    "doi": "10.1016/S1470-2045(25)00537-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00537-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e54d0143-c70a-481d-a9e2-52b01ec61f3d",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Pirfenidone: a new option for radiation-induced lung injury?",
    "abstract": "Radiation-induced lung injury is a clinically significant complication induced by thoracic radiotherapy.1 10–20% of patients present with signs of radiation-induced lung injury, which vary widely according to grade and type of cancer and duration of treatment.2",
    "published": "2025-11-06T23:30:01Z",
    "authors": [
      "Elisabetta Balestro"
    ],
    "doi": "10.1016/S1470-2045(25)00544-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00544-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8d2c0241-ae2b-4658-95df-ebb800160dbe",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?",
    "abstract": "In The Lancet Oncology, Jing Yuan and colleagues present updated results from the SYSUCC-001 trial, evaluating extended adjuvant endocrine therapy with a year of twice daily (metronomic) capecitabine compared with observation in early-stage triple-negative breast cancer following standard chemotherapy.1,2 This post-hoc analysis includes data from 420 of the 434 patients in the trial. The findings confirm the benefit of extended adjuvant capecitabine compared with observation, with statistically significant, double-digit improvements in disease-free survival, distant disease-free survival, and locoregional recurrence-free survival at 10 years.",
    "published": "2025-12",
    "authors": [
      "William M Sikov"
    ],
    "doi": "10.1016/S1470-2045(25)00621-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00621-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b4f5f7f2-d107-46f6-b11e-884eaf74d085",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Of surrogate endpoints, shortcuts, and safety",
    "abstract": "Adjuvant and neoadjuvant systemic drug therapy prevents recurrence and premature death in patients with breast cancer by treating undetectable micrometastatic disease.1 For less toxic treatments, prevention of metastases alone can justify therapy because patients should experience improved quality of life without metastases, but for more toxic or risky treatments improved overall survival might be required.2 When improving overall survival is the agreed-upon goal, both regulators and clinicians must balance the harms from delaying access to treatments later confirmed as improving overall survival (leaving aside the question of magnitude) against the harms of over-treating many patients who they later learn derived no improvement in survival.",
    "published": "2025-12",
    "authors": [
      "Clifford A Hudis, Elizabeth Garrett-Mayer"
    ],
    "doi": "10.1016/S1470-2045(25)00663-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00663-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "6affdb5b-e6fa-4b6e-ad21-17a3847c2923",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Evolution in rectal cancer management",
    "abstract": "Non-operative management after a clinical complete response following neoadjuvant treatment in rectal cancer, often referred to as opportunistic non-operative management rather than intentional non-operative management (ie, up-front treatment for early-stage patients with the aim of non-operative management), is increasingly being implemented. Provided meticulous follow-up, data suggest that non-operative management is feasible, safe, and associated with favourable overall survival.1 However, challenges remain, such as response assessment after neoadjuvant therapy,2 management of near clinical complete response,3 and whether distant control is affected.",
    "published": "2025-12",
    "authors": [
      "Per J Nilsson"
    ],
    "doi": "10.1016/S1470-2045(25)00600-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00600-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5c7494ad-0cd4-4584-8de9-b773e2727c6c",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice",
    "abstract": "Improved molecular classification of glioma has allowed identification of defined patient subgroups with prolonged survival outcomes and the potential for alternative management plans.1,2 Specifically for newly diagnosed patients with lower grade glioma (WHO grade 2–3) harbouring the IDH mutation, initial neurosurgical decision making can be complex due to the balance of optimising disease control and avoidance of long-term neurological morbidity. Additionally, these tumours present with varying neuroradiological appearance related to volume, morphology, and neuroanatomical site, which means interventions require individualisation based on these parameters.",
    "published": "2025-12",
    "authors": [
      "Michael Back"
    ],
    "doi": "10.1016/S1470-2045(25)00592-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00592-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2243657d-e298-4933-a63c-1a6118a0af50",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Focused ultrasound treatments could increase survival in individuals with glioma",
    "abstract": "Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in individuals with glioma.",
    "published": "2025-12",
    "authors": [
      "Antonios N Pouliopoulos"
    ],
    "doi": "10.1016/S1470-2045(25)00552-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00552-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1d23f44d-711a-42ce-bfbf-c008b7c9b590",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Targeting IDH mutation: another milestone, but not the finish line",
    "abstract": "Targeted therapy has entered the stage of glioma management. Mutated isocitrate dehydrogenase (IDH) is the molecular hallmark of WHO grade 2 diffuse low-grade gliomas. In The Lancet Oncology, Timothy F Cloughesy and colleagues compared the mutated IDH inhibitor vorasidenib with placebo for diffuse low-grade gliomas without high-risk features, with 6 months' additional follow-up.1 As expected with the short additional follow-up, this study supports the results of progression-free survival, time to next intervention, and adverse events from the phase 3 trial (INDIGO).",
    "published": "2025-10-29T23:30:02Z",
    "authors": [
      "Asgeir S Jakola, Isabelle Rydén"
    ],
    "doi": "10.1016/S1470-2045(25)00491-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00491-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8155c463-ef21-42f4-b2a9-f662be610958",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Re-establishing human-centred care",
    "abstract": "In 2021, the Global Institute of Psychosocial, Palliative, and End-of-Life Care (University of Toronto, Canada) in collaboration with the Institute of Cancer Policy (King's College London, UK) launched a project called Biomedicine and the Soul of Medicine: Optimising the Balance. As part of this project, a multidisciplinary symposium held over 3 days on Palliative Care, Culture, and the Clinic brought together more than 600 registrants from over 60 countries to explore humanistic and culturally relevant dimensions of cancer care, particularly for patients with advanced disease.",
    "published": "2025-11-02T23:30:02Z",
    "authors": [
      "Cheryl Reeves, David Collingridge"
    ],
    "doi": "10.1016/S1470-2045(25)00604-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00604-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "0f868d8f-1eb1-4e28-a16b-169ecf746814",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home",
    "abstract": "The UK has had serial national cancer control plans (NCCPs) since 1997. Early progress was undeniable, but momentum has waned over the past 15 years, with considerable slippage in cancer survival rankings (eg, the UK is ranked 28th of 33 countries, with similar wealth and income, for 5-year survival with lung and stomach cancer)1 and very poor performance in the International Cancer Benchmarking Partnership cancer policy scorecard.2 At a meeting convened by St George's House (Windsor, UK) in September, 2025, international experts shared experiences of designing and implementing their own plans.",
    "published": "2025-11-06T23:30:03Z",
    "authors": [
      "Mark Lawler, Cary Adams, Eduardo Pisani, Yannick Romero, Sarah Quinlan, Pat Price"
    ],
    "doi": "10.1016/S1470-2045(25)00650-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00650-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5cbc3ca2-43b8-46b4-b4aa-aa5b67b86c79",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] The paradox of generics: broader access, less freedom",
    "abstract": "The Italian National Health Service is founded on universal coverage and equal access to care.1 In this context, sustainability is not optional, but structural; innovative treatments must coexist with responsible use of constrained financial resources. In oncology, where novel therapies have improved outcomes but also driven up costs, generic drugs represent a crucial tool.2 When patent protection expires, bioequivalent formulations can be marketed at lower prices, enabling systems to reduce expenditure on established therapies and reallocate resources to innovation.",
    "published": "2025-12",
    "authors": [
      "Giandomenico Roviello"
    ],
    "doi": "10.1016/S1470-2045(25)00613-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00613-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d62c1a8f-7665-4308-9954-c103c294889d",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SunRISe-4 perioperative safety and TURBT stratification",
    "abstract": "We read with great interest the interim analysis of the SunRISe-4 trial by Andrea Necchi and colleagues.1 This study assessed the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.1 The authors reported a 42% pathological complete response rate with manageable toxicity, underscoring the potential to combine intravesical gemcitabine delivery with PD-1 blockade. Although these findings expand treatment options for cisplatin-ineligible patients, we highlight two points to enhance interpretability and clinical translation.",
    "published": "2025-12",
    "authors": [
      "Wei Luo, Sinan Yang, Chengwei Bi, Yong Yang, Zhiyu Shi"
    ],
    "doi": "10.1016/S1470-2045(25)00553-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00553-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "409dfb71-a9f1-456e-b866-75052e17773a",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SunRISe-4 perioperative safety and TURBT stratification – Authors' reply",
    "abstract": "We thank Wei Luo and colleagues for their insightful comments on our Article.1 We would like to offer some clarifications on the points raised.",
    "published": "2025-12",
    "authors": [
      "Andrea Necchi, Hind Stitou, Sumeet Bhanvadia, Sarah P Psutka"
    ],
    "doi": "10.1016/S1470-2045(25)00671-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00671-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "a69c4f77-20f9-4fa2-a6b0-cc636a0bbb7a",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SBRT in oligometastatic castration-resistant prostate cancer",
    "abstract": "The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in oligometastatic castration-resistant prostate cancer (mCRPC). This study is the second randomised trial, after the ARTO trial,2 to evaluate this combination. Both PCS-9 and ARTO showed improved radiographical progression-free survival with SBRT. However, a significant biochemical response benefit was only observed in the ARTO study, possibly reflecting differences in disease burden (baseline prostate-specific antigen was 3·4 ng/mL in ARTO vs ~10 ng/mL in PCS-9) and imaging strategies, with molecular imaging in ARTO likely identifying earlier disease.",
    "published": "2025-12",
    "authors": [
      "Vérane Achard, Pierre Blanchard, David Pasquier, Paul Sargos"
    ],
    "doi": "10.1016/S1470-2045(25)00565-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00565-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "9a969d25-0f90-4662-9602-1a6ca755be8e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials",
    "abstract": "We read with interest the Article by Daniel Ma and colleagues in The Lancet Oncology.1 Ma and colleagues should be congratulated on completing a randomised trial of de-escalated radiotherapy in patients with p16-positive oropharyngeal squamous cell carcinoma. The authors report progression-free survival, local regional control, freedom from distant metastases, and overall survival as secondary endpoints. The de-escalation protocol resulted in a reduction in progression-free survival, local regional control, and systemic control in patients who received de-escalated treatment with extracapsular extension compared with patients who received standard of care.",
    "published": "2025-12",
    "authors": [
      "Jessica T Lovett, Michael T Wotman, Marshall Posner"
    ],
    "doi": "10.1016/S1470-2045(25)00616-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00616-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "878aeeb0-34c3-4431-92f1-b9e0c691cba0",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply",
    "abstract": "We appreciate the important points raised by Jessica T Lovett and colleagues regarding p16 immunohistochemistry as a surrogate for HPV status in oropharyngeal squamous cell carcinoma in de-escalation studies such as MC1675.1 As they noted, the prognostic implications of p16 and HPV discordance have been previously analysed, such as in a multinational study by Mehanna and colleagues.2 Patients who were p16-positive and HPV-negative had an increased rate of cancer recurrence (hazard ratio 1·92, 95% CI 1·42–2·60).",
    "published": "2025-12",
    "authors": [
      "David M Routman, James S Lewis, Daniel J Ma"
    ],
    "doi": "10.1016/S1470-2045(25)00655-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00655-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "eb29821b-9f5b-439a-91d1-5130e6ffa673",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Corrections] Correction to Lancet Oncol 2024; 25: 1038–52",
    "abstract": "Allaf ME, Kim S-E, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25: 1038–52—In this Article, some of the numbers of patients in the Results and figure 1 have been corrected. The appendix has also been corrected. These corrections have been made to the online version as of Nov 24, 2025.",
    "published": "2025-12",
    "authors": [],
    "doi": "10.1016/S1470-2045(25)00522-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00522-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "236f7a72-3a04-402e-ba26-5ab858ce6dc0",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Corrections] Correction to Lancet Oncol 2025; 26: 1443–53",
    "abstract": "Di Federico A, Stumpo S, Mantuano F, et al. Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol 2025; 26: 1443–53—In figure 4A of this Article, the p value should have read p=0·20, and in figure 5A, the p value should have read p=0·012. These corrections have been made to the online version as of Nov 24, 2025.",
    "published": "2025-12",
    "authors": [],
    "doi": "10.1016/S1470-2045(25)00668-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00668-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "761c32ab-4773-4c64-b625-3476fa98fb8d",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] ESMO Congress 2025",
    "abstract": "Sara A Hurvitz (Fred Hutch Cancer Center, Seattle, WA, USA) and colleagues presented results from the randomised, open-label, phase 3, VIKTORIA-1 trial in 392 patients with HR+/HER2- advanced breast cancer. Medium progression-free survival was 9·3 months in patients receiving the triplet combination of gedatolisib (180 mg, intravenous, once weekly for 3 weeks), fulvestrant (500 mg, intramuscular, every 2 weeks [cycle 1] then every 4 weeks) and palbociclib (125 mg, once daily for 21 days) compared with 2·0 months (hazard ratio [HR] 0·24; 95% CI 0·17–0·35; p<0·0001) for patients receiving fulvestrant alone and 7·4 months (HR 0·33; 0·24–0·48; p<0·0001) for those receiving the doublet combination of gedatolisib plus fulvestrant.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "David Collingridge, Cheryl Lai, Allison Landman, Jamie Prowse, Cheryl Reeves"
    ],
    "doi": "10.1016/S1470-2045(25)00644-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00644-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2d2f9b9e-1f79-4912-84ac-e5bc4c50dc4a",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Eastern Mediterranean Region backs Cairo Call on breast cancer",
    "abstract": "Health ministers in the Eastern Mediterranean region have officially adopted the Cairo Call to Action on Breast Cancer, uniting governments in the region behind a shared framework to address long-standing inequities in cancer care. The agreement outlines priorities to strengthen primary care screening, improve diagnostic and treatment services, expand psychosocial support, and integrate cancer data systems.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "Paul Adepoju"
    ],
    "doi": "10.1016/S1470-2045(25)00645-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00645-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "3c65d784-c369-4546-90b8-25832822e5de",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] New Zealand extends breast cancer screening to 70–74-year-olds",
    "abstract": "As of Oct 15, 2025, New Zealand has, begun a nationwide extension to its breast cancer screening programme, which will now include women aged 70–74 years as well as those already eligible (aged 45–69 years). This will mean tens of thousands more women will be able to access free mammograms once every 2 years, beginning with those aged 70 and 74 years and then expanded over a 4-year rollout to include women aged 71, 72, and 73.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "Tony Kirby"
    ],
    "doi": "10.1016/S1470-2045(25)00646-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00646-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1b072705-b79e-499f-9131-966654f2e296",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Europe's Beating Cancer Plan delayed by “legislative inaction”",
    "abstract": "The success of Europe's Beating Cancer Plan (EBCP) is at risk of being undermined by slow progress on alcohol, tobacco, and nutrition control, according to an implementation findings study published on Oct 20, 2025.",
    "published": "2025-10-30T23:30:01Z",
    "authors": [
      "Elizabeth Gourd"
    ],
    "doi": "10.1016/S1470-2045(25)00657-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00657-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e04c89cf-2823-47e3-8e6f-be794a494f3f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] More e-cigarette users than cigarette smokers for the first time in the UK",
    "abstract": "The number of adults using e-cigarettes or vapes has exceeded the number of cigarette smokers in the UK for the first time, according to figures released on Nov 4, 2025, from the Office for National Statistics.",
    "published": "2025-11-13T23:30:01Z",
    "authors": [
      "Manjulika Das"
    ],
    "doi": "10.1016/S1470-2045(25)00676-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00676-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "688ec1f3-622c-476c-add6-11790b1efec2",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Government shutdown and Medicare changes impact cancer care in the USA",
    "abstract": "The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada.",
    "published": "2025-11-13T23:30:01Z",
    "authors": [
      "Sharmila Devi"
    ],
    "doi": "10.1016/S1470-2045(25)00677-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00677-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ffe540ab-2754-4bae-968e-0cd215a2bb10",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Cancer and comedy: a review of three stand-up specials",
    "abstract": "A cancer diagnosis does not leave much room for humour, but this year I saw three stand-up comedians who found plenty to talk about and took to the stage to share it with London audiences.",
    "published": "2025-12",
    "authors": [
      "Joseph Moody"
    ],
    "doi": "10.1016/S1470-2045(25)00673-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00673-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b8657a41-7049-4323-8541-54f988893f55",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Cancer revolution: science, innovation, and hope",
    "abstract": "A stone's throw from Dublin's Merrion Square, where medical luminaries such as William Stokes and William Wilde plied their craft, stands the airy Georgian structure of the St Stephen's Green Centre. Typically housing an assortment of boutiques and galleries, it is, until Oct 31, 2025, hosting something more unusual, Cancer Revolution: Science, Innovation and Hope, a major new exhibition by Breakthrough Cancer Research.",
    "published": "2025-12",
    "authors": [
      "David Robert Grimes"
    ],
    "doi": "10.1016/S1470-2045(25)00674-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00674-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "485488b0-becd-4730-9550-c8a62c4466db",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Humour in the face of hardship",
    "abstract": "Cancer—It Could Be Worse? (self-published, 2025) is T Fronks’ first book and an energetic, light-hearted addition to the cancer autobiography genre. Fronks, who lives in North Wales, UK, intersperses humorous and optimistic prose with over 50 witty poems and illustrations that she composed during her experience with breast cancer. The memoir presents a bank of enjoyable analogical descriptions and cultural references, from Star Wars to The Muppets, as well as useful practical advice surrounding all things cancer, family, and self-help.",
    "published": "2025-12",
    "authors": [
      "Daniel Mellor"
    ],
    "doi": "10.1016/S1470-2045(25)00675-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00675-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5510a978-178b-4332-950e-12d488810c0b",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] When healing means letting go",
    "abstract": "I once believed that healing meant curing—that a good doctor must fight relentlessly against disease, offering every patient another chance, another line of therapy, another sliver of hope. My instinct was always to do more. But one patient taught me that sometimes, the truest form of healing begins when we learn to let go.",
    "published": "2025-12",
    "authors": [
      "Chinchu Babu"
    ],
    "doi": "10.1016/S1470-2045(25)00659-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00659-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "0b9ec1a9-561e-4538-be1d-64c881f9d4ad",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study",
    "abstract": "Participant selection using the PLCOm2012 risk prediction model with a 6-year risk of at least 1·58% cutoff is more efficient and effective in detecting lung cancer than the NELSON criteria and should therefore be implemented in lung cancer screening programmes.",
    "published": "2025-11-10T23:30:01Z",
    "authors": [
      "Jens Vogel-Claussen, Benjamin-Alexander Bollmann, Katharina May, Susanne Stiebeler, Sabine Dettmer, Anton Faron, Alexander Kuhlmann, Gerald Schmid-Bindert, Rudolf Kaaks, Jörg Barkhausen, Sabine Bohnet, Martin Reck, HANSE investigators"
    ],
    "doi": "10.1016/S1470-2045(25)00490-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00490-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7c0b5f75-9aab-4472-9907-0d87fefc940f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial",
    "abstract": "Pirfenidone in combination with glucocorticoids provides a potential therapeutic strategy for grade 2 or grade 3 radiation-induced lung injury, addressing the unmet clinical need for effective antifibrotic therapy in patients receiving thoracic radiotherapy. Further investigation is needed to validate these findings in patients with worse radiation-induced lung injury than was studied here.",
    "published": "2025-11-06T23:30:04Z",
    "authors": [
      "Zan Hou, Baiqiang Dong, Qiwei Yao, Hualin Chen, Qiuju Shao, Minying Li, Jianyang Wang, Keying Chen, Zhengfei Zhu, Fang Peng, Shihong Wei, Xiao Hu, Jiancheng Li, Meilian Liu, Bin Xu, Siming Zheng, Nan Bi, Shuohan Zheng, Qingqing Xu, Biqi Chen, Chenfei Wu, Rui Li, Wei Chen, Xin Liu, Yuchen Tian, Xuan Li, Suping Guo, Lei Zhao, Yujia Zhu, Ling Cai, Qiaoqiao Li, Li Li, Huilan Zhang, Chen Hu, Luhua Wang, Qiwen Li, Baoqing Chen, Ming Chen"
    ],
    "doi": "10.1016/S1470-2045(25)00515-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00515-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2581bfe3-32c6-4073-a3aa-1c33d0a1192b",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial",
    "abstract": "Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options.",
    "published": "2025-12",
    "authors": [
      "Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang, Yaxin Liu, Yuee Teng, Xiaojia Wang, Jing Cheng, Zhongsheng Tong, Tao Sun, Min Yan, Xin Zhou, Fanfan Li, Jianyun Nie, Zhi-Ming Shao, Changsheng Ye, Yongsheng Wang, Xiaohong Wu, Zhihua Li, Yudong Wu, Huihua Xiong, Hui Li, Lu Gan, Zhaofeng Niu, Juliang Zhang, Qingyuan Zhang, Yueyin Pan, Xinhong Wu, Yi Zhang, Weimin Xie, Yu Xiao, Jinnan Gao, Huadong Zhao, Yongmei Yin, Zhiying Qian, Sanyuan Sun, Hongwei Zhang, Kun Wang, Jinsong Lu, Yong Li, Xinshuai Wang, Xinfeng Yang, Yuting Wang, Quanren Wang, Erwei Song"
    ],
    "doi": "10.1016/S1470-2045(25)00523-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00523-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d09cb846-6ae6-4683-b4f4-73f64b76ec4a",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial",
    "abstract": "In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine provided durable disease-free survival benefit in early triple-negative breast cancer, although the findings should be interpreted with caution given the post-hoc nature of the analysis. Patients with FOXC1-high tumours showed a survival advantage with capecitabine versus observation; if this finding is validated, FOXC1-driven patient selection might be useful to optimise therapeutic responses.",
    "published": "2025-12",
    "authors": [
      "Jing Yuan, Xi-Wen Bi, Xin Hua, Heng Huang, Li Cai, Li Zhao, Qian-Jun Chen, Xin-Xin Chen, Xu-Lin Wang, Ying Lin, An-Qing Zhang, Yong-Yi Zhong, Fei Xu, Jia-Jia Huang, Xin An, Yan-Xia Shi, Xi Wang, Shu-Sen Wang, Cong Xue, Zhong-Yu Yuan"
    ],
    "doi": "10.1016/S1470-2045(25)00545-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00545-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1c6526be-12f6-49ab-812b-53a435dfd658",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials",
    "abstract": "With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations.",
    "published": "2025-12",
    "authors": [
      "Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala, Eleonora Pagan, Christine Solbach, Michael Untch, Carsten Denkert, Vincenzo Bagnardi, Laura Pala, Peter A Fasching, Andreas Schneeweiss, Hans-Joachim Lück, Giuseppe Viale, Tommaso De Pas, Marion van Mackelenbergh, Jens Huober, Volkmar Müller, Theresa Link, Thomas Karn, Mattea Reinisch, Frederik Marmé, Vesna Bjelic-Radisic, Christian Schem, Andreas Hartkopf, Elmar Stickeler, Claus Hanusch, Jens-Uwe Blohmer, Tanja Fehm, Kerstin Rhiem, Richard Gelber, Sibylle Loibl"
    ],
    "doi": "10.1016/S1470-2045(25)00546-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00546-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "666416c7-2052-4844-85cb-50db081c4023",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study",
    "abstract": "At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma.",
    "published": "2025-12",
    "authors": [
      "Shukui Qin, Shanzhi Gu, Stephen L Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Li Xu, Xianglin Yuan, Da Li, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Jinghua Du, Wei Shi, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, CARES-310 Study Group"
    ],
    "doi": "10.1016/S1470-2045(25)00543-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00543-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4a2d1689-7c61-4a52-b94c-056dde81794e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial",
    "abstract": "In pMMR/MSS stage II–III rectal cancer, total neoadjuvant therapy followed by non-operative management allows organ preservation in some patients without compromising distant relapse-free survival, supporting non-operative management as a treatment option in clinical practice.",
    "published": "2025-12",
    "authors": [
      "Alessio Amatu, Giorgio Patelli, Maria Giulia Zampino, Francesca Bergamo, Stefania Mosconi, Federica Tosi, Davide Ciardiello, Sara Lonardi, Giorgia Negrini, Daniela Sibio, Marianna Alessandra Gerardi, Sara Galuppo, Francesco Romeo Filippone, Pietro Carnevali, Simona Borin, Pierluigi Pilati, Elia Poiasina, Erica Bonazzina, Lorenzo Gervaso, Enzo Mammano, Francesco Bracco, Luca Bergamaschi, Gaya Spolverato, Matteo Origi, Uberto Fumagalli Romario, Gianluca Mauri, Nicola Fazio, Edoardo Forti, Giuseppe De Roberto, Chiara Cristofori, Cesare Burti, Luigi Asmundo, Luigi Funicelli, Gaetano Ramondo, Pietro Andrea Bonaffini, Sara Mariano, Luca Lazzari, Silvia Ghezzi, Claudio Isella, Daniela Cantarella, Maria Costanza Aquilano, Luca Bottiglieri, Emanuela Bonoldi, Massimiliano Mutignani, Valter Torri, Enzo Medico, Alberto Bardelli, Silvia Marsoni, Angelo Vanzulli, Mauro Filippo Palazzi, Giovanni Carlo Ferrari, Katia Bencardino, Andrea Sartore-Bianchi, Salvatore Siena"
    ],
    "doi": "10.1016/S1470-2045(25)00542-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00542-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "0dca9935-e4c3-47fe-a2e0-ed296f7af4ee",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial",
    "abstract": "Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatment in patients with stage 3 SCAC.",
    "published": "2025-11-04T23:30:01Z",
    "authors": [
      "Stefano Kim, Jihane Boustani, Soledad Iseas, Dewi Vernerey, Ludovic Evesque, Laurent Quero, Francois Ghiringhelli, Clélia Coutzac, Olivier Bouché, Benoist Chibaudel, Chloé Vernet, Angélique Vienot, David Tougeron, Thierry Nguyen, Magali Rebucci-Peixoto, Aurélia Meurisse, Sarah Chennoufi, Christophe Maritaz, Christophe Borg, INTERACT-ION Study Team"
    ],
    "doi": "10.1016/S1470-2045(25)00605-9",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00605-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7abb09a3-a910-4113-a925-66faef44702e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group",
    "abstract": "The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas.",
    "published": "2025-12",
    "authors": [
      "Philipp Karschnia, Jacob S Young, Maarten M J Wijnenga, Tommaso Sciortino, Nico Teske, Alba Corell, Arthur Wagner, Gilbert Youssef, Yae Won Park, Levin Häni, Stephanie T Jünger, Antonio Dono, Felix Ehret, Eduardo E Mendoza Mireles, Nicolas Neidert, Francesco Bruno, Chad A Tuchek, Thijs van der Vaart, Marco Rossi, Marco Conti Nibali, Lorenzo Gay, Alfred Gramelt, Nitin Tandon, Sung Soo Ahn, Jong Hee Chang, Michael Weller, Arnaud J P E Vincent, Roland Goldbrunner, Daniel P Cahill, Raymond Y Huang, Andreas Raabe, Bernhard Meyer, Juergen Beck, Annette M Molinaro, Susan M Chang, Michael A Vogelbaum, Roberta Rudà, Einar O Vik-Mo, Jorg Dietrich, Yoshua Esquenazi, Stefan J Grau, Patrick Y Wen, Asgeir S Jakola, Oliver Schnell, Lorenzo Bello, Martin J van den Bent, Shawn Hervey-Jumper, Mitchel S Berger, Joerg-Christian Tonn"
    ],
    "doi": "10.1016/S1470-2045(25)00534-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00534-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b8583d92-106a-4ec8-916c-8f03a2775771",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial",
    "abstract": "MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials.",
    "published": "2025-12",
    "authors": [
      "Graeme F Woodworth, Pavlos Anastasiadis, Ahmad Ozair, Jeremi Chabros, Chetan Bettegowda, Chixiang Chen, Jakob V E Gerstl, Christopher Douville, Rania A Mekary, Timothy R Smith, Ying Meng, Cynthia Hawkins, Christopher B Pople, Agessandro Abrahao, Maheleth Llinas, Chinthaka Heyn, Adomas Bunevicius, Ali R Rezai, Anna J S Ball, Kaitlyn Henry, Arjun Sahgal, Erickson Torio, Haoyu Ren, Haroon Ahmad, Harshit Arora, Howard Eisenberg, James Perry, Jeffrey S Carpenter, Kullervo Hynynen, Lily C Pham, Mary Beth Anketell, Mary Jane Lim-Fat, Zhiyuan Xu, Christopher P Cifarelli, Jason P Sheehan, Nathan J McDannold, Dheeraj Gandhi, Alexandra J Golby, Nir Lipsman"
    ],
    "doi": "10.1016/S1470-2045(25)00492-9",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00492-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "55068001-b679-4270-acfb-3fa8849200d7",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial",
    "abstract": "Vorasidenib reduced tumour growth rate and improved seizure control compared with placebo, with no observed negative effects on HRQOL or neurocognition. Additional follow-up supported the robustness of progression-free survival and time to next intervention in patients with grade 2 IDH1/2-mutant diffuse glioma. These findings support the use of vorasidenib in patients with grade 2 IDH1/2-mutant gliomas who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "published": "2025-10-29T23:30:02Z",
    "authors": [
      "Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, Deborah T Blumenthal, Katherine B Peters, Benjamin M Ellingson, Jennifer L Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason, Francois Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F Hottinger, Yoshiki Arakawa, Juan M Sepulveda, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth Maher, Andrew Bottomley, Adriana E Tron, Denise Yi, Dan Zhao, Shuchi S Pandya, Lori Steelman, Islam Hassan, Patrick Y Wen, Ingo K Mellinghoff, INDIGO trial investigators"
    ],
    "doi": "10.1016/S1470-2045(25)00472-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00472-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d81332e8-40f7-4bdd-b924-93a17602d279",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study",
    "abstract": "This study met its primary endpoint, showing high clinical activity of pembrolizumab plus lenvatinib, but with substantial toxicity, in patients with pleural mesothelioma who had progressed after first-line nivolumab plus ipilimumab. This drug combination is promising for future studies in pleural mesothelioma.",
    "published": "2025-12",
    "authors": [
      "Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer"
    ],
    "doi": "10.1016/S1470-2045(25)00514-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00514-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "674e5305-3fb9-4816-944b-72046e965199",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[The Lancet Oncology Commission] The human crisis in cancer: a Lancet Oncology Commission",
    "abstract": "Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every setting, patients and families across global contexts continue to report being unheard, unsupported, and, at times, actively harmed by care structures that prioritise technical precision over human presence.",
    "published": "2025-11-02T23:30:02Z",
    "authors": [
      "Gary Rodin, Amalya Feldman, Dario Trapani, Mac Skelton, Karla Unger-Saldaña, Beverley Essue, Rille Pihlak, Catherine Walshe, William E Rosa, Matthew P Banegas, Miguel Zambrano-Lucio, Rawaz Salah Daood, Ajay Aggarwal, Omar Dewachi, Gilla K Shapiro, Murallitharan Munisamy, Harenthri Devy Alagir Rajah, Shrikant Atreya, Vijay Shree Dhyani, Yek-Ching Kong, Mebin Mathew, Carol Y Ochoa-Dominguez, Arathi Prahallada Rao, Seema Rajesh Rao, Srinagesh Simha, Nancy Preston, Wendy Wing Tak Lam, Hanae Davis, Camilla Zimmermann, Eve Namisango, Christian Ntizimira, Elizabeth Smyth, Madeline Li, Naveen Salins, Nirmala Bhoo-Pathy, Richard Sullivan"
    ],
    "doi": "10.1016/S1470-2045(25)00530-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00530-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4c82b632-6626-4724-b17b-0fcdfe080cab",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Review] Neurocognitive outcomes in patients with brain metastases: a systematic review",
    "abstract": "Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Although advances in radiotherapy delivery techniques have reduced toxicity, the potential interaction with chemotherapy, targeted therapy, and immunotherapy, and the consequent effect on neurocognitive outcomes is poorly characterised. We conducted a systematic review of clinical trials reporting neurocognitive endpoints in patients with brain metastases receiving radiotherapy with or without other concurrent systemic therapies.",
    "published": "2025-12",
    "authors": [
      "Tarek Bou Dargham, Sebastian F Winter, Kristen Batich, Karin Gehring, Michael W Parsons, Jorg Dietrich, Trey Mullikin, Zachary J Reitman, Scott R Floyd, John P Kirkpatrick, Paul W Sperduto, Jona Hattangadi-Gluth, Helen A Shih, Paul D Brown, Minesh Mehta, Erik P Sulman, Katherine B Peters, Eugene J Vaios"
    ],
    "doi": "10.1016/S1470-2045(25)00525-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00525-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5d3b51d0-5cfe-44f6-844c-9ddfcbd8bdec",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Policy Review] SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials",
    "abstract": "Standardising the implementation of patient-reported outcomes (PROs) in clinical trials is crucial for evaluating the benefits and risks of cancer treatments. The Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI) has developed 146 consensus-based recommendations for designing, analysing, interpreting, and presenting PROs in cancer clinical trials. This initiative, undertaken from 2021 to 2025, involved experts, including statisticians, PRO measurement experts, clinicians, and patient representatives from 41 organisations representing regulatory agencies, academia, the pharmaceutical industry, health–technology assessment bodies, and patient advocates.",
    "published": "2025-12",
    "authors": [
      "Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Vishal Bhatnagar, Lisa M Wintner, Antoine Regnault, Anders Ingelgård, Corneel Coens, Saskia le Cessie, Bernhard Holzner, Jane Chang, Martin Taphoorn, Paul Cislo, Johannes M Giesinger, Joseph C Cappelleri, Vivek Pawar, Silene ten Seldam, Elektra J Papadopoulos, Melanie J Calvert, Kenth L Joseph, Andrew Bottomley, Ingolf Griebsch, Juan I Arraras, Guro L Astrup, Ethan Basch, Andrej Belančić, Michael Brundage, Alicyn Campbell, Khadija Rerhou Rantell, Kim Cocks, Nathan Cherny, Sonya Eremenco, Montse Ferrer, Mallorie H Fiero, Christoph Gerlinger, Els Goetghebeur, Ulrich Grouven, Alexandra Lauer, Olalekan Lee Aiyegbusi, Abigirl Machingura, Junki Mizusawa, Geert Molenberghs, Morten Aa Petersen, Jaap C Reijneveld, Jolie Ringash, Gerhard Rumpold, Claudia Rutherford, Chantal Quinten, Kavita Sail, Maxime Sasseville, Willi Sauerbrei, Anja Schiel, Ashley W Smith, Claire Snyder, Galina Velikova, Xin S Wang, Kristin Bjordal, Madeline Pe, SISAQOL-IMI Consortium"
    ],
    "doi": "10.1016/S1470-2045(25)00520-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00520-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e6e6f6ff-49a3-4d81-bff5-75e02905a178",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Policy Review] The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus",
    "abstract": "The Lucerne Toolbox 3 initiative addresses the pressing need for evidence-based integration of digital health and artificial intelligence (AI) technologies in early breast cancer care. The multidisciplinary consortium identified and prioritised 15 crucial medical knowledge gaps across the patient journey, from diagnosis to treatment and survivorship, using a modified Delphi consensus process with 112 unique members from 27 countries and 16 medical societies, trial groups, and patient organisations.",
    "published": "2025-12",
    "authors": [
      "André Pfob, Katja Pinker, Ines Vaz-Luis, Antonio Di Meglio, Maria João Cardoso, Giuseppe Curigliano, Oreste Davide Gentilini, Günther Gruber, Nik Hauser, Jörg Heil, Orit Kaidar-Person, Michael Knauer, Han-Byoel Lee, Sae Byul Lee, Sherene Loi, Meinrad Mannhart, Stella Mastora, Icro Meattini, Rosa Di Micco, Aurelia Noske, Fedro Alessandro Peccatori, Fiorita Poulakaki, Mattea Reinisch, Isabel T Rubio, Charlie Swanton, Christoph Tausch, Marie-Jeanne Vrancken Peeters, Jong Han Yu, Walter Paul Weber, Norman Zerbe, Philip Poortmans, Carsten Denkert, Ritse Mann, Suzette Delaloge, Peter Dubsky, Toolbox 3 Consortium"
    ],
    "doi": "10.1016/S1470-2045(25)00463-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4998aca1-41f2-4bea-a4ac-72c117bfbaee",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Editorial] 2025: an annus horribilis for health in the USA",
    "abstract": "The US Advisory Committee on Immunization Practices vote on Dec 5 to no longer recommend the hepatitis B vaccine birth dose, which had ensured that babies exposed to hepatitis B would not later develop hepatitis B-associated liver damage and liver cancer, caps the most disastrous year for US public health policy. Federal funding cuts had occurred under Joe Biden and mistrust in the nation's health leaders has been waning over time, but the goal of the Trump administration now seems to be to tear down the world's premiere scientific infrastructure.",
    "published": "2025-12-20",
    "authors": [
      "The Lancet"
    ],
    "doi": "10.1016/S0140-6736(25)02588-7",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02588-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7793e9f7-3d1f-4cb1-b4ef-4da576683acd",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity",
    "abstract": "With the rising use of nutrient-stimulating hormone-based therapy for the treatment of obesity, developing oral alternatives could help address the limitations of injectable therapies, including needle phobia, injection site reaction, and storage concerns, and could ultimately improve patient acceptability. Peptide-based oral GLP-1 receptor agonists, such as oral semaglutide, are limited by the need for diet restriction, timing of administration, and low oral bioavailability.1 Peptide-based GLP-1 receptor agonists are also more costly to manufacture and require refrigeration.",
    "published": "2025-12-20",
    "authors": [
      "Edith Wing-Kar Chow, Elaine Chow"
    ],
    "doi": "10.1016/S0140-6736(25)02381-5",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02381-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b054e769-ba5f-45f4-984e-16cecc039b1b",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] Neoadjuvant quadruplet chemotherapy PAXG for pancreatic cancer",
    "abstract": "Perioperative management of localised pancreatic ductal adenocarcinoma (PDAC) is informed by resectability criteria, which consider anatomy together with biological and clinical factors.1 In patients with resectable PDAC, adjuvant mFOLFIRINOX (modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is a standard of care;2,3 however, many are unable to receive this regimen due to inadequate performance status after surgery. Trials have evaluated various neoadjuvant chemotherapy regimens; notably, two randomised controlled trials did not confirm superiority of mFOLFIRINOX or FOLFIRINOX over gemcitabine–nab-paclitaxel (SWOG 1505)4 and gemcitabine with radiation (PREOPANC-2).",
    "published": "2025-11-20T23:30:04Z",
    "authors": [
      "Philip Bredin, Bas Groot Koerkamp, Grainne M O'Kane"
    ],
    "doi": "10.1016/S0140-6736(25)01864-1",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01864-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d0ed8385-e6a0-4f8a-b809-3dc4cd664469",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] Methoxyflurane: a promising non-intravenous, non-opioid analgesic",
    "abstract": "Analgesia in the prehospital setting is a challenging but important priority for first responders. Retrospective military data indicate an association between early analgesia with morphine after injury and lower subsequent risk of long-term sequelae such as post-traumatic stress disorder.1 Yet, data show that the proportion of patients with pain receiving analgesia in the prehospital setting remains low.2,3 This small proportion might reflect difficulty in obtaining intravenous access and concerns regarding haemodynamic side-effects of many analgesic agents such as opioids.",
    "published": "2025-11-20T23:30:01Z",
    "authors": [
      "Michael David April, Steven G Schauer"
    ],
    "doi": "10.1016/S0140-6736(25)01532-6",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01532-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "bc997255-7e36-4e7a-b649-f7e926ec77bd",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] Exploring CAR NK-cell therapy for refractory lupus",
    "abstract": "The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence of cell-based immunotherapies targeting pathogenic B-cell populations. Among these, autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown promise in inducing remission in patients with severe treatment-refractory SLE.1 This innovation addresses a substantial global burden of disease, with epidemiological data estimating more than 3·4 million individuals affected worldwide;2,3 notably, in an Asia–Pacific cohort study, at least 14% of patients were identified as having severe refractory disease.",
    "published": "2025-11-12T23:30:04Z",
    "authors": [
      "Alberta Hoi"
    ],
    "doi": "10.1016/S0140-6736(25)01949-X",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01949-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "3e0c32d7-a170-4ffa-be4b-5a2409e70f44",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] US CDC: a public health agency in critical condition",
    "abstract": "For almost 80 years, the US Centers for Disease Control and Prevention (CDC) has been the nation's immune system, detecting threats early, coordinating rapid responses, and safeguarding population health. Its deep bench of epidemiologists, laboratory expertise, support for health departments, and evidence-based recommendations have fought threats to the public's health. During 2025 that immune system has been compromised, prompting our resignations, following the firing of the US Senate-confirmed CDC Director Susan Monarez on Aug 27, 2025.",
    "published": "2025-11-26T23:30:01Z",
    "authors": [
      "Debra Houry, Daniel Jernigan, Demetre Daskalakis"
    ],
    "doi": "10.1016/S0140-6736(25)02353-0",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02353-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "bfc376a3-7503-4478-8731-3a79eb7e7f28",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] The 2025 Wakley Prize: finding a home in medicine",
    "abstract": "In the call for submissions for the Wakley Prize earlier this year, we quoted Søren Kierkegaard's notion that life “must be understood backwards; but…it must be lived forwards” and encouraged people to reflect on the change they would like to see in medicine.1 We thank everyone who entered the competition and were impressed by the wide-ranging submissions.",
    "published": "2025-12-20",
    "authors": [
      "Joanna Palmer, Phoebe Ashley-Norman, Beth Francis, Gabriella Merry, Sara Phillips, Jessica Pope, Maneet Virdi, Chloe Wilson, Chris Wortley"
    ],
    "doi": "10.1016/S0140-6736(25)02553-X",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02553-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fe58a939-b1f8-4235-9479-617964c28cbb",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Comment] Offline: Watching the watchers (part 3)",
    "abstract": "A strength of the People's Health Movement (PHM), now 25 years old, is its capacious view of health and the determinants of health. In their People's Charter for Health, PHM underlines the economic, social, political, and environmental challenges to health, including war, violence, conflict, and natural disasters. They call for a people-centred health sector in which “governments promote, finance, and provide comprehensive Primary Health Care as the most effective way of addressing health problems and organising public health services so as to ensure free and universal access”.",
    "published": "2025-12-20",
    "authors": [
      "Richard Horton"
    ],
    "doi": "10.1016/S0140-6736(25)02516-4",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02516-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "0c1db9a0-c9ac-4d16-ac92-efa132d228c7",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[World Report] Grants under threat at the US National Institutes of Health",
    "abstract": "Changes to how research grants are assessed and awarded are undermining the world's largest public funder of biomedical research. Washington Correspondent Susan Jaffe reports.",
    "published": "2025-12-20",
    "authors": [
      "Susan Jaffe"
    ],
    "doi": "10.1016/S0140-6736(25)02590-5",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02590-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7efdfd1d-6d99-43f5-86bc-263796268428",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[World Report] UN Environmental Assembly passes AMR resolution",
    "abstract": "The seventh session of the UN Environmental Assembly passed several actions related to health, including improving antimicrobial resistance (AMR) surveillance. Sharmila Devi reports.",
    "published": "2025-12-20",
    "authors": [
      "Sharmila Devi"
    ],
    "doi": "10.1016/S0140-6736(25)02591-7",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02591-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "9acfcb13-b3e8-4276-8622-0d7992903950",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[World Report] Southeast Asia reels after tropical storms",
    "abstract": "Experts warn that thousands could be left at risk of infection, disease, and delayed health-care provision. Megan Tatum reports.",
    "published": "2025-12-20",
    "authors": [
      "Megan Tatum"
    ],
    "doi": "10.1016/S0140-6736(25)02592-9",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02592-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d811bd73-e040-481d-865d-c8842dcc75af",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Perspectives] Highlights 2025: illuminating health stories",
    "abstract": "The images featured in this issue were selected from the many interesting photographs submitted to this year's Highlights photography competition. They capture unique perspectives on a range of health issues from diverse countries, including China, India, Kenya, Mali, Nepal, South Africa, The Gambia, and the USA.",
    "published": "2025-12-20",
    "authors": [
      "Joanna Palmer, Highlights 2025 winning contributors"
    ],
    "doi": "10.1016/S0140-6736(25)02550-4",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02550-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "787c230f-59e4-4e28-9076-fa3e53fca7aa",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] Darfur's humanitarian emergency: a call for immediate action",
    "abstract": "We write with profound moral urgency to highlight the relentless suffering endured by the people of Darfur, Sudan. The ongoing violence driven by militia groups has led to mass displacement and widespread human rights abuses, demanding immediate international attention and collective intervention.1 Silence in the face of this unfolding catastrophe is no longer an option; the scale and severity of the crisis call for urgent action. Since early 2003, Darfur has been engulfed in a ceaseless cycle of conflict marked by recurrent violence, ethnic atrocities, and targeted campaigns against civilian populations.",
    "published": "2025-12-11T23:30:06Z",
    "authors": [
      "Emmanuel Edwar Siddig, Ayman Azhary, Abdallah Elssir Ahmed, Claude Mambo Muvunyi"
    ],
    "doi": "10.1016/S0140-6736(25)02383-9",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02383-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "3549a016-02dc-4c82-99de-79eb878f245f",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] Gender-based violence and displacement in Darfur's war",
    "abstract": "The war in Sudan has resulted in one of the largest and fastest-growing displacement crises of the 21st century. Gender-based violence is both a catalyst for displacement and a profound consequence of it. In Darfur, where communities have endured repeated attacks, women and girls face a collapse of protection that exposes them to severe and widespread sexual violence at every stage of displacement. This convergence of displacement and gender-based violence represents a serious public health emergency that demands urgent global attention.",
    "published": "2025-12-12T23:30:01Z",
    "authors": [
      "Ibrahim Nagmeldin Hassan, Sophia Ahmed"
    ],
    "doi": "10.1016/S0140-6736(25)02384-0",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02384-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2ea160aa-9acc-423e-82da-5542c5821f4c",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] Russia's health workers complicit in abducting Ukraine's children",
    "abstract": "Over the past 3·5 years, the largest child abduction case since World War 2 has unfolded—19 500 children have been forcibly transferred from Ukraine to Russia and Russian-occupied territory.1,2 Russia has used health professionals to conduct and legitimise the abduction of children from Ukraine: psychologists issued necessary documents for children to be transferred to Russia under the guise of medical rehabilitation1 and facilitated the illegal placement of Ukrainian children in Russian families.",
    "published": "2025-12-11T23:30:01Z",
    "authors": [
      "Paige Farrenkopf, Uliana Poltavets, Caitlin Howarth, Nathaniel A Raymond, Danielle N Poole"
    ],
    "doi": "10.1016/S0140-6736(25)02388-8",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02388-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5204bb54-1f0b-4090-bebf-69db4f62ef4c",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] Cerebral palsy: an update on its early detection",
    "abstract": "We read with great interest the Seminar by Inona Novak and colleagues. Their paper provides a broad and eloquent overview of the many aspects of cerebral palsy.1 However, what a paper wins in width, it typically loses in depth. This loss occurred in the text on early detection within the Diagnosis section, including in figure 1. In infants younger than 5 months (corrected age), Novak and colleagues recommend the use of two neurological assessments: the General Movements Assessment (GMA) and the Hammersmith Infant Neurological Examination (HINE).",
    "published": "2025-12-20",
    "authors": [
      "Mijna Hadders-Algra, Uta Tacke, Joachim Pietz, Heike Philippi"
    ],
    "doi": "10.1016/S0140-6736(25)02310-4",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02310-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d5dbb1fe-77e7-4a9e-8737-2aa3bdca22a7",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] Cerebral palsy: an update on its early detection – Authors' reply",
    "abstract": "We thank Mijna Hadders-Algra and colleagues for their engagement with our Lancet Seminar on cerebral palsy.1 The pace of discovery in cerebral palsy exceeding the capacity of any single article to fully describe the condition is indeed a welcome problem. The expansion of evidence and innovation across all aspects of cerebral palsy care, from discovery to implementation, speaks to the commitment of people with lived experience, clinicians, researchers, and philanthropists, who have together driven a transformation in outcomes.",
    "published": "2025-12-20",
    "authors": [
      "Iona Novak, Michelle Jackman, Megan Finch-Edmondson, Michael Fahey"
    ],
    "doi": "10.1016/S0140-6736(25)02311-6",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02311-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "dd19316b-613c-4734-bec6-3b24d3784fe2",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] The need for metabolic health stratification in global obesity forecasts",
    "abstract": "We read with interest the Article by the GBD 2021 Adult BMI Collaborators, which offers valuable insight into the global trends and projections of overweight and obesity through to 2050, and underscores the need for effective public health interventions.1 However, we believe an important nuance requires further consideration.",
    "published": "2025-12-20",
    "authors": [
      "Laurent Fauchier, Mickael Guglieri, Grégoire Fauchier"
    ],
    "doi": "10.1016/S0140-6736(25)01234-6",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01234-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2ce9bdba-f90a-4356-8d3e-05932a213de0",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] The need for metabolic health stratification in global obesity forecasts – Authors' reply",
    "abstract": "We thank Laurent Fauchier and colleagues for their thoughtful comments on our Article.1 We agree that metabolic heterogeneity within obesity is an important dimension of cardiometabolic risk, and that distinguishing metabolically healthy from unhealthy phenotypes will ultimately refine both individual-level and population-level estimates of health burden.",
    "published": "2025-12-20",
    "authors": [
      "Simon I Hay, Marie Ng, Emmanuela Gakidou, Christopher J L Murray"
    ],
    "doi": "10.1016/S0140-6736(25)02312-8",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02312-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f6a96c93-dcac-47c2-a6c0-28af77d241fa",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] The diabetic foot after SWHSI-2: healing is not one size fits all",
    "abstract": "We congratulate Catherine Arundel and colleagues on the publication of the SWHSI-2 trial1 and commend the authors and collaborators on successfully recruiting 686 patients (1895 screened) into this landmark study—an exemplary achievement under any circumstance, but truly outstanding considering the profound disruptions caused by the COVID-19 pandemic to National Health Service (NHS) acute care services. The authors’ effort is a remarkable demonstration of the UK's continued commitment to advancing evidence-based medicine, and it stands as a testament to the resilience of the UK's clinical research infrastructure.",
    "published": "2025-12-20",
    "authors": [
      "Prashanth Vas, Patrick Chong"
    ],
    "doi": "10.1016/S0140-6736(25)02070-7",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02070-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7210cfb9-3d31-4020-bbb7-ea72c68b22a6",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Correspondence] The diabetic foot after SWHSI-2: healing is not one size fits all – Authors' reply",
    "abstract": "We thank Prashanth Vas and Patrick Chong for their positive comments regarding the conduct of the SWHSI-2 study.1 It is pleasing that the authors acknowledge the importance of the study results in the context of diabetic foot care and that the study population reflects the clinical reality of this patient population.",
    "published": "2025-12-20",
    "authors": [
      "Catherine Arundel, Laura Mandefield, Caroline Fairhurst, Athanasios Gkekas, Ian Chetter"
    ],
    "doi": "10.1016/S0140-6736(25)02247-0",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02247-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "849dc0fe-2229-4f4d-a3a4-61f623adcbdf",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Department of Error] Department of Error",
    "abstract": "Gao J, Li M, Sun M, et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet 2025; 406: 2968–79—In figure 3A of this Article, data from the first graph were erroneously added to the second graph. Appendix 2 has also been corrected. These corrections have been made to the online version as of Dec 18, 2025, and the printed version is correct.",
    "published": "2025-12-20",
    "authors": [],
    "doi": "10.1016/S0140-6736(25)02551-6",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02551-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fbd3c4b0-180a-4bba-88d9-42c76d7cb7b0",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Articles] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial",
    "abstract": "In adults with obesity or overweight and type 2 diabetes, statistically superior reduction in bodyweight compared with placebo was demonstrated by once-daily orforglipron as an adjunct to lifestyle modification, with a safety profile similar to other GLP-1 receptor agonists.",
    "published": "2025-11-20T11:45:00Z",
    "authors": [
      "Deborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, Breno Alves, Yiming Mu, Sin Gon Kim, Jens Aberle, Stephen C Bain, Sheryl Allen, Elizabeth Sarker, Qiwei Wu, Adam Stefanski, Irina Jouravskaya, ATTAIN-2 Trial Investigators"
    ],
    "doi": "10.1016/S0140-6736(25)02165-8",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "80f941c6-6731-4f96-8937-68d31f5ef424",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Articles] Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial",
    "abstract": "PAXG significantly improved EFS compared with mFOLFIRINOX in resectable or borderline resectable PDAC. Preopertive PAXG could be considered a standard option for resectable or borderline resectable PDAC. Accordingly, preoperative PAXG should be considered as the standard comparator group for future trials in this setting.",
    "published": "2025-11-20T23:30:01Z",
    "authors": [
      "Michele Reni, Marina Macchini, Giulia Orsi, Letizia Procaccio, Giuseppe Malleo, Catia Carconi, Ilario Giovanni Rapposelli, Katia Bencardino, Mario Scartozzi, Gianpaolo Balzano, Domenico Tamburrino, Barbara Merelli, Elisa Sperti, Giulio Belfiori, Nicole Liscia, Silvia Bozzarelli, Mariacristina Di Marco, Emiliano Tamburini, Michele Milella, Sara Lonardi, Giorgio Ercolani, Michele Mazzola, Diego Palumbo, Valter Torri, Massimo Falconi"
    ],
    "doi": "10.1016/S0140-6736(25)01685-X",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01685-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "115cdbc3-bc6f-4f9b-80da-d424d2169b8c",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Articles] Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial",
    "abstract": "Inhalational methoxyflurane is non-inferior to intranasal fentanyl and intravenous morphine for acute pain management in the prehospital environment, assessed 10 min after administration. Inhalational methoxyflurane serves as a valuable non-intravenous alternative in the early phase of treatment and might bridge the gap to longer-acting analgesics.",
    "published": "2025-11-20T23:30:01Z",
    "authors": [
      "Randi Simensen, Lars Olav Fjose, Kjetil Thorsen, Inge Christoffer Olsen, Marius Rehn, Jostein Hagemo, Live Smalberget, Fridtjof Heyerdahl"
    ],
    "doi": "10.1016/S0140-6736(25)01575-2",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01575-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f6b091d1-e2e5-4063-852b-33f83eb2182d",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Articles] Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China",
    "abstract": "This study suggests that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and indicates that such a therapy might address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost.",
    "published": "2025-11-12T23:30:01Z",
    "authors": [
      "Jie Gao, Mengtao Li, Ming Sun, Yiyi Yu, Ruina Kong, Xia Xu, Suxuan Liu, Qian Chen, Xiaofang Li, Yang Wu, Enshun Xu, Jianmin Yang, Dongbao Zhao"
    ],
    "doi": "10.1016/S0140-6736(25)01671-X",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01671-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5447c2ab-4150-41d5-9100-80454e02b2fc",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Hypothesis] Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?",
    "abstract": "We hypothesise that amylin receptor agonists (eg, pramlintide) and dual amylin and calcitonin-receptor agonists (eg, cagrilintide), which are emerging treatments for obesity and type 2 diabetes, can activate the renin-angiotensin system (RAS) and potentially undermine the cardiorenal benefits of these therapies. Paradoxically, new-generation amylin-based therapies, such as CagriSema, showed substantial blood pressure reductions in phase 3 trials. Beyond amylin's weight loss-mediated effects, we hypothesise that concurrent use of RAS inhibitors (angiotensin-converting enzyme [ACE] inhibitors or angiotensin-receptor blockers) redirects amylin-induced RAS activation towards the protective alternative RAS pathway, which is characterised by vasodilatory, anti-inflammatory, and antiproliferative effects via Mas receptors, potentially explaining part of their therapeutic benefit and cardioprotective and renoprotective potential.",
    "published": "2025-11-06T23:30:01Z",
    "authors": [
      "Marcel H A Muskiet, Massimo Nardone, Patrick C N Rensen, David Z I Cherney, Mark E Cooper"
    ],
    "doi": "10.1016/S0140-6736(25)01776-3",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01776-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "64bbecad-2891-4003-ac68-ce398daeba84",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Lecture] Lessons from Africa: health diplomacy in HIV prevention",
    "abstract": "In these uncertain, volatile, and unprecedented times, the role of science is more important than ever. Scientific advances that benefit humanity and ensure planetary sustainability for current and future generations are essential and addressing the myriad of complex challenges scientists face requires synergistic partnerships and collaborations within and between countries. The COVID-19 pandemic has highlighted our interconnectedness and shared vulnerability but has also underscored the huge divides between high-income countries and low-income and middle-income countries, in terms of manufacturing capacity, research capabilities, investments in science, and access to affordable biotechnologies.",
    "published": "2025-11-04T15:30:01Z",
    "authors": [
      "Quarraisha Abdool Karim"
    ],
    "doi": "10.1016/S0140-6736(25)01976-2",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01976-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fcc11ddc-4c2d-40f4-a969-20a5ea09328c",
    "source_feed": "http://www.thelancet.com/rssfeed/lancet_current.xml",
    "journal": "The Lancet",
    "title": "[Wakley Prize essay] Home",
    "abstract": "With trepidation, I stood frozen to the spot, holding the cold, metal key between my fingers. Bracing myself, I slid the key into the lock and turned it. Treading lightly up the stairs, heart pounding in my ears. My daily ritual, walking on eggshells, never sure what awaited me at home each day when I returned from school.",
    "published": "2025-12-20",
    "authors": [
      "Donna Wakefield"
    ],
    "doi": "10.1016/S0140-6736(25)02467-5",
    "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02467-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "777fdefc-e63d-4bd7-b703-02d626ba3dd1",
    "source_feed": "http://www.thelancet.com/rssfeed/eclinm_current.xml",
    "journal": "eClinicalMedicine",
    "title": "[Articles] Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study",
    "abstract": "These data suggest that panel-based PGx testing is cost-effective, which, together with the clinically beneficial outcomes already demonstrated in the PREPARE study, provides additional evidence of the need to implement PGx into clinical practice.",
    "published": "2025-12-16T06:14:53Z",
    "authors": [
      "Vasileios Fragoulakis, Jesse J. Swen, Margarita-Ioanna Koufaki, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Anne Cambon-Thomsen, Erika Cecchin, Ka-Chun Cheung, Vera H.M. Deneer, Mathilde Dupui, Siv Jonsson, Candace Joefield-Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Lisanne E.N. Manson, Emmanuelle Rial-Sebbag, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cathelijne H. van der Wouden, Cristina Lucía Dávila-Fajardo, Vita Dolžan, Munir Pirmohamed, Gere Sunder-Plassmann, Giuseppe Toffoli, Henk-Jan Guchelaar, George P. Patrinos, Christina Mitropoulou"
    ],
    "doi": "10.1016/j.eclinm.2025.103686",
    "link": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00620-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7982d3aa-4297-48a3-9d7c-80144ffc857d",
    "source_feed": "http://www.thelancet.com/rssfeed/eclinm_current.xml",
    "journal": "eClinicalMedicine",
    "title": "[Articles] Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study",
    "abstract": "Despite being a de-escalating and anthracycline-free neoadjuvant treatment approach, the triplet combination therapy showed promising efficacy and safety, signifying a crucial step toward the optimization of chemoimmunotherapy for early TNBC.",
    "published": "2025-12-16T06:14:53Z",
    "authors": [
      "Fei Wang, Xiaopeng Hao, Cuizhi Geng, Ying Lin, Zhenzhen Liu, Peifen Fu, Qiang Liu, Zhigang Yu, Zefei Jiang"
    ],
    "doi": "10.1016/j.eclinm.2025.103709",
    "link": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00643-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "dd84d00e-be97-4e3b-ab87-ca58f511ccd6",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Editorial] Ageing in South-East Asia",
    "abstract": "On Oct 15, 2025, members of the WHO South-East Asia region signed the Colombo Declaration. The declaration, signed by nine of the ten member countries (ie, Bangladesh, Bhutan, North Korea, India, Maldives, Nepal, Sri Lanka, Thailand, and Timor-Leste), commits to strengthening primary health care to ensure healthy ageing in the region. This action is important as the region, which is home to approximately 25% of the world’s population, is experiencing rapid population ageing. WHO predicts that the number of people aged 60 years or older in the South-East Asia region will almost double in the next 25 years—from 11·3% in 2024 to 20·9% in 2050.",
    "published": "2025-11-28T11:42:52Z",
    "authors": [
      "The Lancet Healthy Longevity"
    ],
    "doi": "10.1016/j.lanhl.2025.100807",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00126-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7d62543f-3711-4658-981c-0747e994ba3c",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Comment] A pragmatic application with clear personal impact",
    "abstract": "I remember with unremitting clarity the last year of my mother’s life, although it happened 24 years ago. She opted to undergo elective knee surgery after a successful hip replacement 4 months earlier despite being somewhat frail due to her advanced age (late 70s) and having multiple myeloma. She went from the hospital to a rehabilitation hospital and, subsequently, to a nursing home. She died 8 months after the elective knee surgery.",
    "published": "2025-11-26T06:00:01Z",
    "authors": [
      "Carolyn E Schwartz"
    ],
    "doi": "10.1016/j.lanhl.2025.100795",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00114-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "3b9eed78-2ccc-452f-ba24-bb813148f39f",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Comment] Hidden risks: long-term mortality after invasive pneumococcal disease",
    "abstract": "Pneumococcal diseases are among the most common vaccine-preventable infections worldwide.1 Among them, invasive pneumococcal disease (IPD) is the most severe clinical manifestation. To reduce the burden of IPD, various vaccination strategies such as routine immunisation of children with pneumococcal conjugate vaccines (PCVs) and vaccination of adults at risk through direct administration of pneumococcal polysaccharide vaccine (PPSV23) or PCVs have been implemented.",
    "published": "2025-11-21T17:42:44Z",
    "authors": [
      "Carmen Ardanuy, Jordi Càmara"
    ],
    "doi": "10.1016/j.lanhl.2025.100785",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00104-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "02c6fe6c-aa7a-44a5-acee-f7ff60a8203e",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Correspondence] Pain and suicide in ageing societies: closing a structural blind spot",
    "abstract": "In their Article published in The Lancet Healthy Longevity, Amy J Morgan and colleagues1 reported that community-based gatekeeper training improved suicide literacy among older men. Their trial highlights the urgent need for tailored prevention strategies in late life. Older adults (ie, those aged ≥65 years) have a double burden: they have the highest prevalence of chronic pain (up to 60% in the community and 80% in institutional care)2,3 and the highest suicide rates of any age group (32·7 per 100 000 for men aged ≥85 years vs 18·9 per 100 000 for men overall).",
    "published": "2025-11-11T11:43:02Z",
    "authors": [
      "Nilson N Mendes Neto, Jessika M Mendes, Thiago Duarte, Brendon Stubbs"
    ],
    "doi": "10.1016/j.lanhl.2025.100787",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00106-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e63efe79-6bfc-4a54-8ce0-243eeee17a2c",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Feature] Highlights of the EuGMS congress 2025",
    "abstract": "How to further integrate geroscience into geriatric medicine was a topic of discussion at the 21st European Geriatric Medicine Society congress in Reykjavik, Iceland (Sept 24–26, 2025).",
    "published": "2025-11-13T11:42:27Z",
    "authors": [
      "Philippa K Harris"
    ],
    "doi": "10.1016/j.lanhl.2025.100793",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00112-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f04b257a-98b3-4562-87fb-e56ac9939cbf",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Articles] Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1",
    "abstract": "In cognitively unimpaired, psychologically pre-screened adults, APOE disclosure by a trained health-care provider was generally safe and well tolerated, consistent with results from previous studies. To our knowledge, this is the largest study experience of APOE disclosure to date, especially for homozygotes, and is notable for the older age of participants compared with previous research. These results are timely and important given anticipated increases in APOE disclosure to guide clinical decision making once an Alzheimer’s disease prevention treatment is approved for cognitively unimpaired adults or if patients’ family members are interested in genetic testing.",
    "published": "2025-11-27T16:43:01Z",
    "authors": [
      "Jessica B Langbaum, Angela R Bradbury, Brian L Egleston, Elisabeth McCarty Wood, Carolyn M Langlois, Emily A Largent, Kristin Harkins, Claire M Erickson, Shana D Stites, Emma Oyen, Marie-Emmanuelle Riviere, Fonda Liu, Ana Graf, Scott Y H Kim, Joshua D Grill, Eric M Reiman, Pierre N Tariot, J Scott Roberts, Jason Karlawish"
    ],
    "doi": "10.1016/j.lanhl.2025.100778",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00097-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "89721e90-fb72-4f0d-9a79-d3f2e441645e",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Articles] Significant new disability after major non-cardiac surgery in older adults aged 65 years and older in Canada: a multicentre prospective cohort study",
    "abstract": "One in six older adults in this cohort experienced new disability or death at 6 months following major surgery, increasing to one in five patients by 1 year. Preoperative assessment of frailty, cognitive status, and social supports could enhance shared decision making, care planning, and functional recovery.",
    "published": "2025-11-26T06:00:01Z",
    "authors": [
      "Duminda N Wijeysundera, Shabbir M H Alibhai, Martine T E Puts, Keying Xu, Julian F Daza, Calvin Diep, Karim S Ladha, Tyler R Chesney, C David Mazer, Alice C Wei, Sahar Ehtesham, Emily Hladkowicz, Janneth Pazmino-Canizares, Stephen Choi, Melinda Davis, Derek Dillane, Emmanuelle Duceppe, Eric Jacobsohn, Gianni R Lorello, David B MacDonald, Su-Yin MacDonell, Matteo Parotto, Pablo E Serrano, Janet M van Vlymen, Daniel I McIsaac, FIT After Surgery Investigators"
    ],
    "doi": "10.1016/j.lanhl.2025.100789",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00108-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "2e3df0d6-4dba-467f-8c4b-0e73268d71f1",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Articles] Long-term survival after invasive pneumococcal disease: a matched cohort study using electronic health records in England",
    "abstract": "IPD was associated with increased mortality at least 5 years after infection. These findings emphasise the value of IPD prevention and the need for more research into the clinical management of people who have had IPD. Long-term mortality should be incorporated in cost-effectiveness analyses for pneumococcal vaccines.",
    "published": "2025-11-21T17:42:44Z",
    "authors": [
      "Anne Suffel, Fariyo Abdullahi, Eleanor Barry, Jemma Walker, Nick Andrews, Zahin Amin-Chowdhury, Shamez N Ladhani, Daniel Grint, Helen I McDonald, Ian Douglas, Kathryn E Mansfield, Edward P K Parker"
    ],
    "doi": "10.1016/j.lanhl.2025.100775",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00094-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5fe13c03-c610-4aae-9525-08f4da3bda8e",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Personal View] Understanding changes in complex care needs over time: key research insights into multimorbidity trajectories",
    "abstract": "Multimorbidity, the coexistence of multiple chronic diseases or conditions, poses a major challenge for health-care systems worldwide. Traditional research has largely relied on cross-sectional studies, offering limited insight into multimorbidity evolution over time. This Personal View advocates for a paradigm shift towards longitudinal approaches that capture multimorbidity trajectories. Tracking the sequence, pace, and severity of disease accumulation can enhance our understanding of underlying mechanisms, inform early interventions, and improve patient care.",
    "published": "2025-11-25T11:43:14Z",
    "authors": [
      "Amaia Calderón-Larrañaga, Elisa Fabbri, Ana Isabel González, Rafael Perera-Salazar, Nina Grede, Bruce Guthrie, José M Valderas, Caterina Gregorio, Christiane Muth, Davide L Vetrano, Gabriele Meyer, Luigi Ferrucci, Jeanet W Blom, Kerstin Bernartz, Lara Schürmann, Maria Hanf, Martin Scherer, Michael A Steinman, Mieke Rijken, Sharon Straus, Susan M Smith, Victor M Montori, Svetlana Puzhko, Marjan van den Akker"
    ],
    "doi": "10.1016/j.lanhl.2025.100790",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00109-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5a693aad-b113-4045-9d23-1ff727f6ee44",
    "source_feed": "http://www.thelancet.com/rssfeed/lanhl_current.xml",
    "journal": "The Lancet Healthy Longevity",
    "title": "[Personal View] Bridging the age gap: improving representation of older adults in clinical trials for type 2 diabetes and chronic kidney disease",
    "abstract": "Chronic kidney disease (CKD) is common among older adults, with more than a third of individuals older than 65 years having moderate to severe CKD globally. Management of CKD in older adults is often complex because of multiple comorbidities, polypharmacy, and frailty. However, older adults remain under-represented in clinical trials for both type 2 diabetes (T2D), which is the leading risk factor for CKD, and CKD itself. Recent analyses show consistent low representation of older adults in T2D trials.",
    "published": "2025-11-22T12:42:09Z",
    "authors": [
      "Changyuan Yang, Hanneke Joosten, Lynne Chepulis, Fabiana Rossi Varallo, Peter van Dijk, Deidra C Crews, Priya Vart"
    ],
    "doi": "10.1016/j.lanhl.2025.100796",
    "link": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00115-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "271d71b3-1384-46e8-b89a-b3870f8e6e22",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "JAMA",
    "abstract": null,
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2024.19017",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842617",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "438610b1-8a44-479d-80e8-4e186d08ed57",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Audio Highlights November 21, 2025",
    "abstract": "Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2024.19018",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842099",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "30ebc990-4b06-45f0-b9a5-d94a4ae41a6a",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Sunshine and Health",
    "abstract": "There is something appealing in the doctrine of the healthfulness of fresh air and sunshine. It almost seems as though they represent instinctive preferences on the part of mankind so far as modes of living are concerned. These atmospheric factors play a large part in the propaganda of medical climatology, yet it has not been easy to define their potencies in terms of concrete benefits or to describe their functions in the language of scientific endeavor. The demonstration that the sun’s rays may destroy certain microorganisms was welcomed, for it gave the semblance of tangible advantage to sunlight. The antirachitic effects of exposure to sunlight discovered during the last few years indicate the therapeutic and prophylactic efficacy of sunlit air. Hope has been awakened of further advantages to be learned, and warnings have even been issued against the possible harmfulness of overexposure to such types of radiation in the belief that it may be healthful, curative or even injurious, depending on the “dosage.”",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2024.19019",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841712",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "dd01555e-d75b-44d0-a663-1754e494ab97",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Hush",
    "abstract": "laryngitis do you want to know a secret?",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17291",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841691",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e0212aeb-2521-4c37-9f3e-7746e28b4ac1",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "“How Strangely Sweet”: Laryngitis and the Quiet Quirkiness of Senryu",
    "abstract": "Although not nearly as ubiquitous as haiku, senryu is a Japanese poetic form that more loosely follows the familiar 5-7-5 syllable line arrangement. Traditionally, the older haiku form was used by masters such as Bashō to address themes of nature and the seasons, its quiet artistry evoking zen-like tranquility; in contrast, senryu, arising a century later, was conceived as entertainment, more like light verse, that often gently poked fun at human foibles. When haiku entered the English language via the work of imagist poets such as Ezra Pound and Amy Lowell, the US confessional tendency created perhaps a hybrid haiku-senryu variant, which is delightfully carried forward in “Hush.” The opening 3 lines are at once utterly concise and yet cleverly loaded, beginning an interplay between contemplative solemnity and confessional jest. The medical diagnosis of laryngitis, at once banal and yet potentially serious, provides an apt basis for such a double-natured study of the loss of one’s voice. “How strangely sweet/this vow of silence” the speaker ironically states, the whispery senryu form itself an embodiment of his near voicelessness and his attendant bemusement. The more portentous “laryngoscopy/sibilances rising/from the deep” mixes both the worry at, and the beauty in, what our bodies may contain. Yet the self-reflection and seasonal awareness of haiku and the witty urbanity of senryu are both expressed in the deft final lines: “first frost/more and more/I just smile,” reminding us that when poetry and medicine meet, we are soothed.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17294",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841690",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c7d77d97-c50e-43b5-b462-c7736fc363f8",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants",
    "abstract": "The 2024-2025 COVID-19 vaccines effectively protected against SARS-CoV-2 infection and emergency department visits, hospitalizations, and deaths during the circulation of JN.1 subvariants, new research finds.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19733",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841663",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "aa931b6b-5192-4a29-9f31-fd65102930db",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "FDA Approves Nonhormonal Treatment for Menopausal Hot Flashes",
    "abstract": "The US Food and Drug Administration (FDA) recently approved elinzanetant, marketed as Lynkuet, for moderate to severe hot flashes due to menopause, the third FDA-approved nonhormonal treatment option for vasomotor symptoms, which include hot flashes and night sweats.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19735",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841662",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c1e04291-f778-456a-a57e-dcf5cfe4052f",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Meta-Analysis: Viral Infections May Raise Cardiovascular Risks",
    "abstract": "Viral infections may elevate cardiovascular risks, according to a meta-analysis recently published in the Journal of the American Heart Association. The findings support the importance of preventive measures such as vaccines, the authors wrote.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19736",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841661",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b9ade51d-5dd9-4e90-b5f7-73781dadbc2b",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Bacterial Vaginosis Treatment Should Involve All Partners, ACOG Says",
    "abstract": "New guidelines from the American College of Obstetricians and Gynecologists (ACOG) recommend concurrent therapy for those experiencing recurring bacterial vaginosis (BV) and their sexual partners.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19737",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841660",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "18df59a1-3da1-4db5-b664-b1b17559ec42",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Updated Flu, RSV Vaccination Recommendations for Immunocompromised People",
    "abstract": "New guidelines from the Infectious Diseases Society of America (IDSA) urge influenza and respiratory syncytial virus (RSV) vaccination for immunocompromised individuals.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19738",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841659",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e8f0b429-40ed-4e2a-a823-78b0288aed66",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "AAP: Leucovorin Not Recommended for Autism",
    "abstract": "In new interim guidance, the American Academy of Pediatrics (AAP) said it does not recommend leucovorin use for children with autism.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19739",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841658",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b2a9b48a-abf6-41c1-a2bc-53835b9873a9",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Circadian Rhythm and Cardiometabolic Health",
    "abstract": "This Medical News article discusses a new American Heart Association scientific statement on the importance of optimizing one’s circadian system to reduce the risks of obesity, hypertension, type 2 diabetes, and cardiovascular disease.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.22365",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841657",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "bc405b5c-89c5-4619-b3fa-a666995e174a",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "New Insights on Gluten Sensitivity",
    "abstract": "This Medical News article discusses new research on the global prevalence and characteristics of nonceliac gluten sensitivity.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.22366",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841656",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "349d5959-9891-4dad-8d05-c34f0b67a926",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Arsenic Exposure Reduction and Mortality",
    "abstract": "This prospective cohort study uses data from adults enrolled between 2000 and 2002 in Araihazar, Bangladesh, to examine whether reductions in well-water arsenic exposure, measured using urinary arsenic levels, are associated with lower mortality from chronic diseases, including cancer and cardiovascular disease.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19161",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841553",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "9b4c3653-9a72-48cb-9ce6-19553aa4c743",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Lower Urinary Tract Symptoms in Males",
    "abstract": "To the Editor A recent Review provided a thorough overview of lower urinary tract symptoms (LUTS) management, highlighting behavioral therapy as first-line treatment. However, we have concerns about potential overestimation of the efficacy of behavioral therapy for patients with urinary retention. Although the Review suggested that behavioral therapy, including pelvic floor exercises and timed voiding, is effective for LUTS, the cited studies supporting this claim largely excluded patients with significant postvoid residual (PVR) volumes. For instance, a study by Burgio et al excluded men with PVR greater than 150 mL and evaluated the efficacy of behavioral therapy in combination with pharmacotherapy. Additionally, Burgio et al excluded patients with PVR greater than 250 mL, and Brown et al excluded those with PVR greater than 200 mL.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17850",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841317",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "cd18b117-c8d2-4730-bcfa-b39026a4ec04",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Lower Urinary Tract Symptoms in Males",
    "abstract": "To the Editor We have concerns that a recent Review about male LUTS used incorrect terminology.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17852",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841316",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "0e8a4ac9-fac6-4a63-bab9-4412af95b50f",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Lower Urinary Tract Symptoms in Males",
    "abstract": "To the Editor A recent Review on LUTS in men is widely useful but lacked discussion of LUTS in young men.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17854",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841315",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "5cf7178c-cd3d-4190-94f6-7085a3ed5f58",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Lower Urinary Tract Symptoms in Males—Reply",
    "abstract": "In Reply We appreciate the letters about our recent article. We agree with Dr Zheng and colleagues that there are limited data for behavioral therapy in men with urinary retention. In fact, Figure 2 recommends that men found to have urinary retention be referred for urologic evaluation rather than behavioral therapy. As Zheng and colleagues point out, the definition of urinary retention and elevated PVR level is variable in the medical literature. We chose a 300-mL cutoff as a fairly specific definition for urinary retention but acknowledge that this definition may vary in clinical practice. The concept, however, of using behavioral therapy for men with normal PVR level and LUTS is evidence based.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17856",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841314",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "cb292a98-0bf9-4681-8e8e-02786e3fcd4a",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Evolving Hospital-at-Home to Meet the Needs of Children",
    "abstract": "This Viewpoint describes the hospital-at-home model for delivering hospital-level services in the home, barriers to implementation of pediatric hospital-at-home programs, current opportunities for these programs, and policy changes needed to support their growth and meet the changing needs of pediatric populations.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20238",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841311",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "323f9b1b-e73e-4626-b4c5-d707fca2534b",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Review on Uveitis",
    "abstract": "To the Editor I enjoyed the recent Review of uveitis in adults, but one cause of uveitis was omitted—Coccidioides infection.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17735",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841073",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "22fa3735-6c99-43b9-ae77-2a56b8dfc8fb",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Review on Uveitis—Reply",
    "abstract": "In Reply We thank Dr Oscherwitz for an informative letter that will be particularly helpful to clinicians practicing in the US and to those caring for travelers and migrants from endemic regions. Highlighting Coccidioides infection as a cause of uveitis usefully complements the discussion in our review of fungal etiologies and reminds readers that local epidemiology should shape the differential diagnosis.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17737",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841072",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "099076c8-0ced-43dc-a654-6d67eb120050",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "AI in the Lab—Will AI Really Change Drug Discovery?",
    "abstract": "In this episode of JAMA+ AI Conversations, I interview Ajamete Kaykas, PhD, chief exploration officer at insitro, a biotech company aiming to combine machine learning with wet lab work to identify new treatments. We discuss everything from the future of scientists in the AI era to whether AI will really open the door to a new generation of therapeutics.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.21010",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841059",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e6e3525e-7168-4de2-8177-b91986368277",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Telehealth and Online CBT-Based Treatments for High-Impact Chronic Pain",
    "abstract": "To the Editor Dr DeBar and colleagues’ recent randomized clinical trial evaluated telehealth and online cognitive behavioral therapy (CBT) interventions for chronic pain management. Their findings are timely and contribute to the discourse on expanding accessible treatments for chronic pain. Nevertheless, several critical issues require further consideration to better contextualize and interpret the results.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17416",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841057",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "34d42fb5-050b-4652-850a-1dddae85ee5e",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Telehealth and Online CBT-Based Treatments for High-Impact Chronic Pain",
    "abstract": "To the Editor Dr DeBar and colleagues demonstrated the sustained efficacy of telehealth-delivered CBT in reducing pain severity and improving functional outcomes among patients with high-impact chronic pain over 3 to 12 months. Notably, coach-led interventions exhibited superior adherence and clinical benefits compared with self-guided formats.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17420",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841056",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "5b70589f-3b62-4153-b6a2-78575ba6ce79",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Telehealth and Online CBT-Based Treatments for High-Impact Chronic Pain—Reply",
    "abstract": "In Reply Several questions raised by Jiang and colleagues and by Xu and colleagues about our Original Investigation may be best addressed by considering the nature of pragmatic trials and related study design decisions. Our primary focus was on a critical question for health care decision-makers, namely, the relative benefits of 2 widely accepted remote forms of CBT for chronic pain. We compared these treatments with each other and with usual care when provided in a manner feasible for use in everyday care settings—delivered by nonexpert staff, broadly inclusive of a variety (and often multiple types) of disabling chronic pain and commonly co-occurring conditions. As such, we prioritized use of the types of widely available clinical data used in frontline clinical care such as self-reported pain (currently the gold standard because no biomarker for chronic pain exists) and electronic health record data. While modest, the magnitude of effect reported was consistent with that observed in other rigorously conducted randomized clinical trials, including drug trials, for which there is no evidence of sustained effect after treatment as was observed in our study. In contrast to many prior studies, our study focused on a particularly challenging clinical population, ie, individuals with high-impact chronic pain (pain that significantly interferes with daily function). The fact that the 2 active study interventions demonstrated the benefits seen in pain-related and other secondary outcomes is noteworthy. Taken together, our study findings provide a more realistic assessment of the effects of remote CBT programs for pain when delivered in the context of everyday clinical care.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17418",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841055",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "15e9318c-02c2-41b4-ae36-d403cba1e57b",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "The Last Night",
    "abstract": "In this narrative medicine essay, a rheumatologist compares her last night on call as a resident with her last night on inpatient call 40 years later and the years between.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.18916",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2841053",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b5142571-525e-4bf8-b246-f395646cbe42",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "A Revision to Organ Failure Assessment in Critically Ill Patients",
    "abstract": "Modern intensive care of critically ill patients is evolving. Nearly 1 in 5 hospitalized patients receive intensive care, and there are new diseases, treatments, and approaches to organ support. Many intensive care unit (ICU) patients develop acute, vital organ failure—a nefarious and unremitting cause of death—and structured measures of vital organ function help to quantify illness severity. These scores were developed almost 50 years ago and were meant to be generic and independent of the cause of multiple organ failure. Now, organ failure scores are still incorporated into contemporary risk prediction models, syndromic criteria like Sepsis-3, and disaster triage tools and are also used to compare ICU populations and outcomes from randomized clinical trials. Organ failure scores are used widely by clinicians, researchers, and quality improvement teams. But how these scores should evolve with changes in modern intensive care is debated.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20255",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840827",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f934d421-6831-424b-97cc-b097b72aae66",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Development and Validation of the SOFA-2 Score",
    "abstract": "This article describes the data-driven development and validation of the final SOFA-2 score.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20516",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840822",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "fe666bbd-94c4-435a-b699-56912a6f9f1d",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Pattern-Mixture Models for Missing Data",
    "abstract": "This JAMA Guide to Statistics and Methods article discusses designing and implementing clinical trials to minimize the number of missing data.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.18109",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840739",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b239b84b-0a69-4d1c-96c5-987a6a483359",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Artificial Intelligence and Diabetes Prevention",
    "abstract": "As of 2021, an estimated 38.4 million people in the US had diabetes, and 97.6 million with prediabetes were at increased risk of diabetes. Approximately 70% of people with prediabetes develop diabetes over their lifetime. Furthermore, there is evidence that people with prediabetes have increased risk of the microvascular and macrovascular complications of diabetes, even if they do not meet diagnostic criteria for diabetes. Hence, the American Diabetes Association supports screening, diagnosis, and intervention for people with prediabetes. These recommendations are the direct result of findings from landmark trials such as the US Diabetes Prevention Program (DPP) that enrolled participants with prediabetes and tested strategies to prevent or delay the progression to overt diabetes. Major findings included reduction of onset of type 2 diabetes by 58% with lifestyle modification and 31% with metformin compared with placebo during the 3-year DPP randomized trial, and durability of the initial interventions to prevent or delay diabetes for more than 20 years after randomization in the extension DPP Observational Study, as well as cost-effectiveness of intensive lifestyle modification and health care cost savings from metformin.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20099",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840704",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "2bf99485-a3c2-430a-abcb-b7937708aa8e",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program",
    "abstract": "This randomized trial examines whether referral to an artificial intelligence–led lifestyle intervention based on the Diabetes Prevention Program (DPP) is noninferior to referral to a human-led DPP in achieving recommended thresholds for weight loss, hemoglobin A1c, and physical activity among adults with prediabetes and overweight or obesity.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19563",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840703",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "57703911-c03f-463e-a7fb-13ddcce3a7d1",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "State Mifepristone Regulation Following  GenBioPro v Raynes",
    "abstract": "This Viewpoint discusses the GenBioPro v Raynes decision and what it could mean for other cases challenging medication abortion restrictions on preemption grounds.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.19752",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840574",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b0a01931-f448-4d83-9d89-ec76c5885940",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "ACIP Standards for Assessing Evidence",
    "abstract": "This Viewpoint discusses Institute of Medicine (IOM) standards for clinical guideline development and measures taken by the Advisory Committee on Immunization Practices (ACIP) to bring ACIP in line with those standards; describes ways in which these standards and measures have not implemented by ACIP; and calls for ACIP recommendations to meet IOM standards.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20060",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840473",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f687a673-139c-432f-a1de-49ac28ec053a",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "The Make America Healthy Again Strategy Report",
    "abstract": "This Viewpoint discusses the deficiencies of the Make America Healthy Again Commission’s strategy report and proposes known evidence-based interventions to address chronic diseases in children.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20093",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840472",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "ea062c20-8bda-4d1d-8e65-c49b98814146",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Recurrent  Clostridioides difficile  Infections",
    "abstract": "This JAMA Insights discusses the epidemiology, diagnosis, and treatment of recurrent Clostridioides difficile infections.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.18089",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2840352",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f242e8c7-fb73-4d68-b728-549531dd54fe",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Medicaid Spending for Undocumented Immigrants",
    "abstract": "This cross-sectional analysis examines emergency Medicaid spending relative to total Medicaid expenditures and identifies state factors associated with variation in spending.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.18709",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2839711",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "4adcf1b0-5dce-4563-8a65-30ea5e25b5e3",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Patient Information: Early-Onset Gastrointestinal Cancer",
    "abstract": "This JAMA Patient Page describes early-onset gastrointestinal cancer and its risk factors, signs and symptoms, management, prognosis, and prevention measures.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.14795",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2839634",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "8d71eae5-f326-4545-a119-fed9fdb5ebf3",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Tracking County-Level Measles Cases in the US",
    "abstract": "This case series explores an online data collection and sharing infrastructure that centralizes tracking of measles cases from counties across the US.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.17812",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2839096",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "857f6496-2be5-422a-a59b-c968cdf7b6aa",
    "source_feed": "https://jamanetwork.com/rss/site_3/67.xml",
    "journal": "JAMA Current Issue",
    "title": "Cutaneous Melanoma: A Review",
    "abstract": "This review summarizes current evidence regarding the epidemiology, pathophysiology, diagnosis, and treatment of cutaneous melanoma.",
    "published": "Tue, 16 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.13074",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2838001",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "56e62198-f9ed-455c-a9bb-777833340e5a",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Audio Highlights December 19, 2025",
    "abstract": "Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.15660",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843231",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_startingpage",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "a34aae8b-4d23-4313-89c9-e516f49c8d35",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Measles Deaths Decline, but Outbreaks Persist",
    "abstract": "The World Health Organization (WHO) reported that global immunization efforts have led to an 88% decrease in measles deaths from 2000 to 2024.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20025",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843204",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "61dc8ff2-4fe0-4e9e-9ddf-10957e37aa0f",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "GLP-1 Drugs Linked With Chronic Cough",
    "abstract": "People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a new study found.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20026",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843203",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "6356ccd1-9b31-4b84-bb12-38401cd615c4",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Shingles Vaccine May Slow Dementia Progression",
    "abstract": "Although previous﻿ research has shown associations between herpes zoster (HZ) vaccination and reduced dementia occurrence, recent findings demonstrate that it also may protect against early cognitive impairments and death due to dementia.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20027",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843202",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "4f5845df-6f6d-445a-a0e3-bc2405b0c9f7",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "FDA to Use Advanced AI for Premarket Reviews, Other Complex Tasks",
    "abstract": "The US Food and Drug Administration (FDA) will now be leveraging agentic artificial intelligence (AI), a more advanced form than generative AI, for more complex tasks including premarket reviews, postmarket surveillance, inspections, and compliance checks.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20028",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843201",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "78325369-0ee2-4992-a952-69f3251be6d4",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Untreated Sleep Apnea May Elevate Parkinson Disease Risk",
    "abstract": "Results from a new study suggest that obstructive sleep apnea (OSA) is associated with an increased risk of Parkinson disease (PD). Early treatment—specifically with continuous positive airway pressure (CPAP)—was found to diminish the link.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20029",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843200",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f4eb2eda-96a2-4039-a910-1788e583948b",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Adverse Childhood Experiences Decline in US",
    "abstract": "The prevalence of adverse childhood experiences seems to be trending down, according to a study published in JAMA Network Open.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20030",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843199",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "7f2efc35-1d81-4620-a54d-e7dea5b67795",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Geriatrics Training for All",
    "abstract": "This Medical News article discusses challenges and progress toward more widespread geriatrics training in medical school, residency, and health systems.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.22810",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843198",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "567ca274-10f7-4b57-92a6-dcbfd67e9d62",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "What to Know About the New H3N2 Flu Strain",
    "abstract": "This Medical News article discusses a new H3N2 influenza strain, called subclade K, that may lead to a more severe flu season.",
    "published": "Fri, 19 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.25205",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843197",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "315212c2-da31-4664-b5af-53835560728c",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Together",
    "abstract": "In this narrative medicine essay, a medical student describes his minute-by-minute experience during the recent shooting at Brown University and reflects on the power of love and small acts of care that surfaced amid fear.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.26160",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843191",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c0173db0-b6a9-40a2-a185-aad5fc666444",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Influenza A(H3N2) Subclade K Virus",
    "abstract": "This Perspective examines the currently circulating influenza A(H3N2) subclade K virus, including antigenic variants, vaccine effectiveness, and countermeasures.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.25903",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843190",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "8495ac73-3d8f-468e-8502-1bbcdeb1f7ea",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "State Vaccine Law and Policy—A New Threat to Public Health",
    "abstract": "This Viewpoint discusses the importance of understanding the evolution and current trajectory of state-level vaccine requirements for assessing the stability of the nation’s immunization infrastructure.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.25904",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2843189",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e9a95400-5acf-44b9-b1f0-710784893448",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "AI and Health",
    "abstract": "JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, spoke with JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, for JAMA+ AI Conversations.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.22071",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842978",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_startingpage",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f6465180-6a9d-4662-bc2b-e0782fe32b7a",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Use of Controls in Medical Research",
    "abstract": "Otho B. Ross Jr., M.D., Charlotte, N. C.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.15661",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842977",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f1570912-49ea-4a1d-a4e3-418c2918ba2c",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Abortion Access in Los Angeles Managed Medicaid Networks",
    "abstract": "This secret shopper study assesses current capacity to provide abortion care within California’s managed Medicaid networks in Los Angeles County after passage of federal legislation temporarily banning Medicaid payments to large family planning organizations.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.21870",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842976",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e28ac8b3-21b0-4e70-82b8-25c8c5ca50dc",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Overcoming Bias in a Fall Prevention Program in Resource-Limited Areas",
    "abstract": "To the Editor A recent research article reported a reduction of 1 or more falls over 12 months among older adults living in rural China after a program integrating balance with functional exercises and a community-engaged education protocol compared with usual care (29.7% vs 38.3%; odds ratio, 0.67; 95% CI, 0.48-0.91). The study’s pragmatic, cluster-randomized trial across 128 villages is commendable. Yet the open-label design, a self-reported primary end point, and substantially greater participant-clinician contact in intervention villages together create a plausible pathway for differential outcome misclassification—specifically, underreporting of falls in intervention clusters driven by expectancy and social-desirability effects. Such differential measurement is a recognized risk in cluster trials and should be anticipated and explored.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.21041",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842975",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f54b694f-ae4f-454c-b3a8-53336dd4ecdb",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Overcoming Bias in a Fall Prevention Program in Resource-Limited Areas",
    "abstract": "In Reply We thank Dr Zhang for the insightful comments on potential outcome measurement bias in our trial. We welcome this opportunity to address these methodological considerations within the broader context of implementing evidence-based geriatric care in resource-constrained settings.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.21039",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842974",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "4c9f03f3-2925-4c05-b656-162b82b485ac",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Avoidant/Restrictive Food Intake Disorder",
    "abstract": "This JAMA Patient Page describes avoidant/restrictive food intake disorder and its risk factors, symptoms, diagnosis, and treatment strategies.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.20077",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842972",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "43a9606d-9b66-4acf-b50d-502051ea6bab",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Tiny Bubbles",
    "abstract": "In this narrative medicine essay, a hospitalist describes a day with her son who has severe autism and notes what most people don’t: the moments of joy she and her son share.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.21709",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842971",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "fa41c6c3-ec8b-4be6-99d7-3c99cbd1bd90",
    "source_feed": "https://jamanetwork.com/rss/site_3/onlineFirst_67.xml",
    "journal": "JAMA Online First",
    "title": "Research Culture Harming Medical Education",
    "abstract": "This Viewpoint discusses how mass-production strategies that prioritize quantity over quality in research publication are undermining the principle of knowledge advancement in medical training.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jama.2025.23320",
    "link": "https://jamanetwork.com/journals/jama/fullarticle/2842970",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "a265e948-ec6d-4187-bb57-d9eab8d793e4",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Error in Byline and Funding Section",
    "abstract": "The Research Letter titled “Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN,” published online October 30, 2025, was corrected on December 18, 2025, to fix an error in the byline and author contributions section regarding the name of the first author, Eric Milan Mukherjee, MD, PhD. Where it previously had Milan Mukherjee as the author’s last name, it now correctly reads Mukherjee. In addition, the funding statement was changed to reflect that it was Dr Mukherjee who was funded by the Vanderbilt University Medical Center internal career development award rather than Dr Martin-Pozo. This article was corrected online.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5748",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843093",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "12551f87-1d2b-4f00-b1b9-fa121b503f2a",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "JAMA Oncology",
    "abstract": "JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2024.4669",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843061",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "be3b0f79-7957-4f26-8da5-768157ba65e5",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Emerging Artificial Intelligence Technologies for Risk Assessment and Management in Acute Myeloid Leukemia",
    "abstract": "This review examines the use of artificial intelligence in managing acute myeloid leukemia.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3601",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840876",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "84bd1ea3-534e-4a8f-8f05-638e0f1b75cb",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Muscle Mass, Fragility, Weight Loss, and Cancer Treatment",
    "abstract": "This Viewpoint discusses adverse effects associated with pharmacologic treatment of patients with cancer and overweight or obesity and emphasizes the importance of lifestyle modifications.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4521",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840875",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "dbf684dc-8472-428a-98c6-636f59949aa3",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Long-Term Physical Activity for Prevention of Digestive System Cancers",
    "abstract": "Zhang et al should be congratulated on their epidemiologic study evaluating whether physical activity can lower the risk of developing or dying of a digestive system cancer, exploring how much physical activity is required, and how consistent it should be.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4159",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840513",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "23f78d10-1c9f-4f6e-9e19-84d840e3d500",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN",
    "abstract": "This cross-sectional study examines the association of immune checkpoint inhibitor use with Stevens-Johnson syndrome, toxic epidermal necrolysis.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4349",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840512",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b57fda1e-b0bb-4f7d-829d-1a9b1155418f",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Rethinking End Points in Modern Oncology Trials—Beyond the  P  Value",
    "abstract": "To the Editor We read with great interest the meta-epidemiological analysis of modern phase 3 cancer trials by Sherry et al. Clarifying several points would be helpful.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4340",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840510",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "20267fd4-32ec-43ef-a93e-73d59a43b817",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Rethinking End Points in Modern Oncology Trials—Beyond the  P  Value",
    "abstract": "To the Editor We read with great interest the meta-epidemiological analysis by Sherry et al of 791 phase 3 oncology trials. The authors reported that only 28% of trials demonstrated an overall survival (OS) benefit and only 11% showed a global quality-of-life (QoL) improvement. They concluded that QoL appears both underevaluated and underreported and note that most QoL analyses were unadjusted for baseline, which lose efficiency and add bias compared with baseline-adjusted methods. We commend this study but would like to discuss several methodological and interpretative issues.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4343",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840509",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "6eef41f3-d0ab-416d-8a03-40fb1fc6238c",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Rethinking End Points in Modern Oncology Trials—Beyond the  P  Value—Reply",
    "abstract": "In Reply We appreciate the interest in our study regarding overall survival (OS) and quality of life (QoL) in phase 3 oncology trials.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4346",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840508",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1240dbd0-e1a2-4c83-8a8e-084bb56fb3c2",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality",
    "abstract": "This cohort study using data from 3 large US prospective cohorts assesses whether adherence to the recommended physical activity level measured in metabolic equivalent task over time is associated with lower digestive system cancer risk.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4185",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840507",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "24d6c9b2-45eb-4490-b174-c6d263e64922",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women",
    "abstract": "This cohort study estimates the difference in breast cancer risk associated with different hormonal contraceptive formulations.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4480",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840506",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "cabf61e8-edab-4446-8579-e10ee384a692",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Errors in Results and Figure 2",
    "abstract": "The Original Investigation titled “Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial,” published online March 14, 2024, and in the May 2024 issue of JAMA Oncology, contained errors in the Results section as well as Figure 2. An incorrect follow-up time variable was used to calculate the time to first grade 3 adverse event, which affected the analysis presented in Figure 2 and the corresponding hazard ratio, 95% CI, and P value reported in the text (the correct hazard ratio is 0.89; 95% CI, 0.51-1.55; P = .46). Additionally, the correct estimate (SE) and P value for bowel scores in follow-up were 0.57 (0.06); P &lt; .001. These corrections do not change the study’s overall conclusions or interpretations. This article was corrected online.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4707",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840220",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "53b83c8c-13e3-4220-95ea-baf071378438",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Do All Breast Cancer Survivors Need to See a Cardiologist?",
    "abstract": "Little is known about the contribution of breast cancer treatments to the long-term development of heart failure (HF) and/or cardiomyopathy (CM) in patients. For some treatments (eg, anthracyclines), specific recommendations for cardiac surveillance are based on the total cumulative dose received. For ERBB2 (formerly HER2)-targeted treatments, monitoring largely occurs in the setting of active treatment, with little guidance for subsequent surveillance or risk assessment. The expanding number of breast cancer survivors, with cardiovascular disease as an important competing cause of mortality, brings attention to understanding who is at risk for HF/CM after breast cancer treatments and whether preventive cardiac surveillance is warranted.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4141",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840219",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e7356b43-c31c-4221-bca5-d96e4be967f2",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Trends in Dexrazoxane and Cardiovascular Health Care Use for Children With AML",
    "abstract": "This cohort study examines trends in dexrazoxane and cardiovascular health care use for children with acute myeloid leukemia (AML) in the US.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4365",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840218",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "25a97405-de12-4dc9-bd7f-581122a45843",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Power Limits in Body Mass Index, Activity, and Cancer Risk",
    "abstract": "To the Editor The study by Joffe et al provides insights into body mass index (BMI), physical activity, and subsequent neoplasm risk in survivors of childhood cancer. Its large cohort (22 716 participants) and tumor subtype analysis are strengths. However, the lack of statistical power analysis for rare tumor subtypes, like breast and colorectal cancers, limits interpretation of null findings.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4172",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840217",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c91762c2-d746-47e4-9aaa-1cb8ebbba734",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Power Limits in Body Mass Index, Activity, and Cancer Risk—Reply",
    "abstract": "In Reply We would like to thank Guo for their interest in our recent publication, and for their thoughtful comments regarding the statistical power of our null findings for subsequent breast, colorectal, and hematologic neoplasms.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4175",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840216",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "cf21bc23-64f0-436a-a001-8f2ec42ff645",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Risk Prediction Model for Heart Failure or Cardiomyopathy After Breast Cancer Treatment",
    "abstract": "This longitudinal cohort study investigates whether a risk prediction model can estimate the 10-year risk of developing heart failure or cardiomyopathy in women receiving systemic treatment for invasive early-stage breast cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4178",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840215",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b3663849-cc5e-4302-90ef-c3f52172449c",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Can We Use Credit Data to Assess Cancer Financial Hardship?",
    "abstract": "This Viewpoint explores using credit data to identify patients with cancer at risk of financial hardship and adverse treatment outcomes.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4371",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840214",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "24ffc89d-2849-4245-8e58-0819803c9af5",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ",
    "abstract": "This nonrandomized clinical trial examines surgical outcomes following preoperative breast magnetic resonance imaging in women with ductal carcinoma in situ.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4079",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840007",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "d39508d0-806f-42cc-adab-ffce7339b75b",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Active Monitoring, Surgery, and Radiotherapy for Prostate Cancer",
    "abstract": "This secondary analysis of the PROTECT randomized clinical trial assesses the association between cribriform-positive and cribriform-negative prostate cancer and risk of metastasis in patients who underwent active monitoring, surgery, or radiotherapy.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4125",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840006",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1c5d71a6-5d90-498a-b1fb-7ad735d1ea2c",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Unexpected Results of Induction Chemotherapy vs Adjuvant Chemotherapy",
    "abstract": "To the Editor We read with interest the results of the phase 3 randomized clinical trial by Guo et al that investigated the important question if induction chemotherapy (IC) was superior to adjuvant chemotherapy (AC) when added to a backbone of concurrent chemoradiotherapy (CCRT) in patients with N2-3 nasopharyngeal carcinoma (NPC). For IC, the investigators used the triplet combination of paclitaxel-cisplatin-fluorouracil (TPF), whereas doublet cisplatin-fluorouracil (PF) was used for AC. The trial was powered to detect a 12% difference in progression-free survival (PFS) in favor of IC, and enrolled 324 patients, with 162 patients in each group. However, this was a negative trial with comparable 3-year PFS between IC plus CCRT and CCRT plus AC, contrasting the results of the NPC-0501 trial by the Hong Kong NPC study group, which showed an improvement for PFS in favor of IC, albeit subtle differences exist between both trials. Intriguingly, in the present study, IC was associated with poorer local control compared with AC.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4092",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840005",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "0a69ba10-0aab-4133-bf12-d03001640e63",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Unexpected Results of Induction Chemotherapy vs Adjuvant Chemotherapy—Reply",
    "abstract": "In Reply On behalf of my coauthors, I thank Chua and Lim for taking the time to read our article and share their thoughtful comments.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4095",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840004",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1dee86fa-c1c5-4a29-a677-e9da93786ac0",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma",
    "abstract": "This cohort study evaluates artificial intelligence–detected tumor-infiltrating lymphocytes on pretreatment melanoma metastases as a biomarker for response and survival in patients treated with first-line anti–programmed cell death 1 protein (PD-1) with or without anti–cytotoxic T-lymphocyte–associated protein 4.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.4072",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840003",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "25c7c5d4-c7d6-467e-b89a-fc4191602644",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment",
    "abstract": "This consensus review establishes guidelines for the rational and efficient use of next-generation sequencing−based technology in the clinical management of sarcoma.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3608",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2840002",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "0e6ee47e-b1db-46be-9084-fca3dd2231a4",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility",
    "abstract": "This cross-sectional study examines absolute neutrophil count–related racial and ethnic disparities in cancer clinical trial eligibility using Duffy null status.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3869",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839922",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1bff366b-7c52-4ef6-907e-2f9561369eab",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology",
    "abstract": "To the Editor Heyward et al presented an important contribution to the growing literature on outcomes of immune checkpoint inhibitors (ICIs) in older adults with non–small cell lung cancer (NSCLC). By linking Surveillance, Epidemiology, and End Results (SEER)–Medicare data with modern treatment records, the authors attempted to quantify the trade-off between survival gains and immune-related adverse events (irAEs) associated with ICI-based regimens. Their key finding that ICI plus chemotherapy in first-line systemic therapy resulted in improved survival at the cost of increased severe irAEs is both clinically meaningful and methodologically ambitious. We believe that several aspects of the analytic approach and interpretation warrant further discussion.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3786",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839921",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1cd010b8-d128-46e2-ad2b-406e0acc05dd",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology",
    "abstract": "To the Editor The study by Heyward and colleagues addresses a critical unmet need in immuno-oncology: quantifying clinical trade-offs between survival gains and immune-related toxic effects in non-small cell lung cancer (NSCLC) subgroups typically excluded from clinical trials. Their novel harm-benefit metric, excess severe immune-related adverse events (irAEs) per life-year gained, provides actionable insights for personalized decision making, particularly in older adults and patients with autoimmune diseases where clinical evidence remains scarce.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3789",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839920",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "7d5ec76e-13a5-42d0-8bcc-fb2a3ef639d9",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology—Reply",
    "abstract": "In Reply We thank Yue et al and Li for their careful read and insightful comments on our recent work.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3792",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839919",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "ea6046a7-9701-461e-954b-3a264a19bfa0",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Risk Factors for Valvulopathy Among Childhood Cancer Survivors",
    "abstract": "This case-control study aims to identify treatment-related risk factors for valvular heart disease in a large European cohort of long-term childhood cancer survivors.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3863",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839918",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "a93acc7a-bab0-47a1-8f87-d5b1bb610147",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women",
    "abstract": "This study evaluates population-based breast cancer risk estimates for those with established pathogenic variants overall and stratified by first-degree family history of breast cancer and other factors.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3875",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839917",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "4c442216-fdcd-4b75-9def-a53d17b8803c",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "An Oncologist’s Journey on Becoming a Patient",
    "abstract": "This essay describes an oncologist’s experience as a patient with pancreatic cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3882",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839916",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "66422884-530d-4cd7-adaa-50cab5da72a5",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Prostate-Specific Membrane Antigen PET for Postoperative Recurrence of Prostate Cancer",
    "abstract": "When it comes to prostate cancer, we have long been torn between the Charybdis and Scylla of overtreatment and undertreatment. The study by Belliveau et al, published in JAMA Oncology, attempts to navigate such a path forward in the postoperative space.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3625",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839400",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "381274da-bae4-4c41-b4d3-7e69cd820e9e",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer",
    "abstract": "This observational study examines the clinical response to cisplatin and carboplatin shortages among patients with lung cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3768",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839399",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "ce710f16-f47f-408a-9093-d53cc6106434",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Concerns Regarding Follow-Up Duration and End Point Validity",
    "abstract": "To the Editor Nikitas et al demonstrated favorable tolerability of stereotactic body radiotherapy (SBRT) to the prostate bed following radical prostatectomy. Notably, no measurable differences in urinary, bowel, or sexual function were observed over a 2-year period.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3780",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839398",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "98657545-222f-4a5b-95d0-d53c407ef1f9",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Concerns Regarding Follow-Up Duration and End Point Validity—Reply",
    "abstract": "In Reply We thank Endo and Kami for their interest in our recent article.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3783",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839397",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "70aacd12-67f1-4de1-a9df-ea755396b431",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Intensification of Salvage Radiotherapy After Radical Prostatectomy",
    "abstract": "This randomized clinical trial examines the association of prostate-specific membrane antigen positron emission tomography (PET)–guided intensification of salvage radiotherapy with failure-free survival among patients with prostate cancer after radical prostatectomy.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3746",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839396",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "6295d420-9cf7-4989-9731-430006fdf81b",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "The Definition of Cure in Colon Cancer",
    "abstract": "This pooled analysis of 15 phase 3 randomized clinical trials classifies long-term outcomes of colon cancer years after surgery and explores when the incidence of true relapses of the initial colon cancer approaches 0% to define cure in this disease.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3760",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839395",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "abf1c09d-2c0c-4679-953d-2de3371ab957",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "The Breakup Letter",
    "abstract": "Dear Hair, We must break up. I hope it’s only a trial separation. It’s not me, it’s not you, It’s cancer. I will miss pinning you up, or wearing you down, Depending if I’m up or down. And the tension of a ponytail, is a dull ache I now grieve. Or the graceless frizz from rain’s humidity. I long to curse my gray hair, And pay too much for its disguise. But vanity has no place in my furious fight, To one day brush a head of silver. And my battle requires a hairless skull. To scare cancer back to hell.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3458",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839394",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "aa661122-7639-4936-b5ab-49020065686a",
    "source_feed": "https://jamanetwork.com/rss/site_159/174.xml",
    "journal": "JAMA Oncology Current Issue",
    "title": "Contraceptive Choices and Breast Cancer Risk",
    "abstract": "This Viewpoint explores the injunction against taking hormonal contraceptives among premenopausal women at increased risk for breast cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.3743",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2839393",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "df6030f2-7d75-450a-8926-00d8f3d5f128",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Glucagon-Like Peptide-1 Receptor Agonists and Cancer",
    "abstract": "To the Editor Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become among the most widely used medications worldwide, though their use has raised concerns regarding a potential increased risk of cancer. Dai et al conducted a retrospective cohort study assessing the incidence of 13 distinct cancers, which yielded a pooled hazard ratio (HR) of 0.83 (95% CI, 0.76-0.91), suggesting an overall decreased risk, although a notable increase in risk was identified for kidney cancer. The authors described the risk as follows: “However, GLP-1RAs were associated with a marginally nonsignificant increased risk of kidney cancer (HR, 1.38; 95% CI, 0.99-1.93; P = .04).” The term marginally nonsignificant likely reflects the fact that the lower bound of the CI was 1.0, despite the P value of .04, which is conventionally considered statistically significant. This apparent discrepancy may be attributable to differences in the statistical methods used to calculate the CIs vs the P value.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5364",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843057",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "20f18914-bcb1-4f16-8d95-782be3742092",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Glucagon-Like Peptide-1 Receptor Agonists and Cancer",
    "abstract": "To the Editor Dai and colleagues, along with others, have recently highlighted the potential role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cancer prevention. Specifically, the study by Dai et al used a target trial emulation (TTE) method, which enhances causal inference and has the potential to inform clinical guidelines and policy. The TARGET Statement on reporting of observational studies of emulating a target trial states that TTE studies can be used to answer causal questions about the comparative effects of interventions when randomized clinical trials are unavailable or not feasible. This is the case here because there are no available cancer prevention trials using GLP-1RAs. Because clinical trials would require large sample sizes, long-term follow-up, prohibitive costs, and risk of contamination, this direct evidence is unlikely to ever materialize. A TTE approach is therefore justified, but we believe there are 2 major deviations of the TTE methodology in the study by Dai et al that weaken the presented evidence.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5367",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843056",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f10ea2c6-435c-4991-ab83-0175cd72f1bb",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Glucagon-Like Peptide-1 Receptor Agonists and Cancer—Reply",
    "abstract": "In Reply We thank Etminan et al and Harris and colleagues for their thoughtful comments on our recent article. Their thoughtful letters raise complementary points regarding statistical interpretation and study design, which we address in turn.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5370",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843055",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "a94be654-c18c-49b1-a314-77ef36bf92fa",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions",
    "abstract": "This cohort study evaluates the association between quadrivalent human papillomavirus vaccination and high-grade vulvovaginal lesions among women in Sweden.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5511",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843054",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "d518280b-e6fd-41d6-ab28-82b4decd5835",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens",
    "abstract": "This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5376",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843053",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "bb33d2c4-ce6e-4fba-8c80-4eadcab76b91",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Managing Nonfinancial Conflicts of Interest in Oncology Research",
    "abstract": "This Viewpoint advocates for greater disclosure of nonfinancial conflicts of interest in oncology research to safeguard the credibility of such work.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5247",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2843052",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "e0c137d5-ee2f-44c8-a56b-8983c02c0c17",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Error in Denominator in Results Text",
    "abstract": "The Original Investigation titled “Iodine Seed−Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer,” published online on August 28, 2025, and in the October 2025 issue, incorrectly stated in the Results section that the denominator used to calculate the percentage of patients diagnosed with invasive residual breast disease who received adjuvant systemic treatment was 215; instead, these 34 patients (16%) were from among the 135 patients with ypN0 disease. This article was corrected online.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5629",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2842811",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "d6aadd7e-1408-4899-acb2-f7bf5c66521a",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Unraveling the Complexity of Cancer-Related Cognitive Impairment in Breast Cancer",
    "abstract": "Cancer-related cognitive impairment (CRCI) is an important clinical problem that affects many patients with cancer and includes difficulties in memory, attention, processing speed, and executive function. Studies including patient-reported outcomes (PROs) suggest that 50% to 75% of patients receiving chemotherapy experience CRCI. These problems negatively affect daily functioning and can persist for many years. Given that CRCI exists in the short and long term, better understanding of the effect of disease and various treatment combinations on CRCI and whether there are differential effects in the magnitude of CRCI by treatment regimen and the contributions of host factors is needed.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5088",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2842810",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "a900f036-3f09-433e-b051-56de90345181",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Definitive Radiotherapy for Organ Preservation in Nasal Cavity Cancers",
    "abstract": "This cohort study evaluates the use of definitive rhinectomy and adjuvant radiotherapy with or without chemotherapy for patients who declined rhinectomy or had unresectable disease.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5241",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2842809",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "775e00a4-a328-4afe-8f45-dd7872dcab95",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women",
    "abstract": "This secondary analysis of the RxPONDER randomized clinical trial assesses patient-reported cognitive impairment by menopausal status among women with breast cancer treated with chemoendocrine therapy vs endocrine therapy alone.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5220",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2842808",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "470604eb-4df9-42dc-b448-913d0411ca86",
    "source_feed": "https://jamanetwork.com/rss/site_159/onlineFirst_174.xml",
    "journal": "JAMA Oncology Online First",
    "title": "Stroke in Patients With Cancer",
    "abstract": "This Viewpoint recommends changes in the short-term treatment of patients with cancer-associated stroke.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoncol.2025.5234",
    "link": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2842807",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c72021c3-fd6a-438c-bd7e-378493c5370d",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "JAMA Otolaryngology–Head &amp; Neck Surgery",
    "abstract": "Mission Statement: To advance the patient-centered, evidence-based practice of otolaryngology–head and neck surgery by publishing scientifically rigorous and innovative research, reviews, and commentary. Our journal serves as a vital resource for clinicians, researchers, educators, and trainees by providing high-quality, peer-reviewed content focused on improving the understanding and treatment of ear, nose, and throat conditions. We are dedicated to fostering dialogue and action on critical issues in otolaryngology, including the education and training of health care professionals, quality improvement, and the ethics and economics of equitable health care delivery.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2024.3469",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842420",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "14613e4d-2898-4785-8b21-833c0327b5b2",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Mind, Machine, and Medicine",
    "abstract": "This Viewpoint summarizes the presidential address of the president of the American Head and Neck Society.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4108",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2840474",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "3417a170-a9c0-47ef-90e1-73366819cc1b",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Multiomic Selection of Cancer-Testis Antigens as Precision Immuno-oncologic Targets in Head and Neck Cancer",
    "abstract": "This cross-sectional study evaluates specific cancer-testis antigens as potential precision immuno-oncologic targets in both previously untreated (de novo) and recurrent head and neck squamous cell carcinoma tumors.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.3563",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2840416",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "252a74ca-be91-44f5-b37d-e56b10b885e8",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Are We Training Too Many Head and Neck Fellows?",
    "abstract": "This Viewpoint discusses the purpose of head and neck fellowship and what the correct number of practicing head and neck surgeons is.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.3471",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2840414",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "b0ce8735-0e8d-4db6-aecb-cee1e90d3da9",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Reimbursement for Thyroid Surgery and Potential Solutions",
    "abstract": "This economic evaluation characterizes trends in Medicare reimbursement for thyroid surgery and provides evidence for future discussions on payment reforms.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.3696",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2840186",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "06b11a73-4522-41c1-b231-b84e91e02305",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Contralateral Tonsil in p16-Positive Tonsil Squamous Cell Carcinoma",
    "abstract": "This Viewpoint examines current surgical guidelines and emerging evidence regarding the optimal treatment of patients with p16-positive oropharyngeal squamous cell carcinoma.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2410",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2840185",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "31971725-2b6a-40d6-8dea-d3a84ba5ae77",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Improving Palliative Care for Patients With Head and Neck Cancer",
    "abstract": "In this issue of JAMA Otolaryngology–Head and Neck Surgery, Fu et al used data from the Ontario Cancer Registry to evaluate palliative care (PC) use in 11 135 patients with head and neck cancer (HNC) during their last year of life. They found that PC was utilized in 90% of patients and was associated with increased monthly costs at the end of life, a greater number of emergency department visits and hospital admissions, and a lower likelihood of dying at home compared to non-PC recipients. The majority of PC was received in the inpatient setting and was initiated in the last 6 months of life. Gastrostomy and/or tracheostomy tube placement occurred in 11% of patients in the last year of life and was associated with increased costs that were partially mitigated by early (&gt;6 months before death) PC involvement. The authors conclude that early PC involvement may attenuate the costs associated with tracheostomy and gastrostomy tube use in the last year of life but that it does not reduce the use of aggressive hospital-based care or facilitate home deaths. These findings highlight the high symptom burden associated with HNC end-of-life care and demonstrate gaps in the current delivery of PC to this population.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2688",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2838819",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "83529a5c-bd4c-4d90-9993-e9f07b1dea11",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Palliative Care With Tube Use and End-of-Life Quality and Costs in Head and Neck Cancer",
    "abstract": "This cohort study assesses the association of palliative care and tracheostomy or gastrostomy tubes with end-of-life costs among patients with head and neck cancer during the last year of life.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2687",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2838814",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "21b6d96c-3c5d-4973-9551-6ebc5a5007b0",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Barriers and Timely Postoperative Radiation Therapy in Head and Neck Cancer",
    "abstract": "This cohort study investigates potential barriers to timely postoperative radiation therapy, defined as initiating radiation care within 6 weeks of surgery.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2824",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2838772",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "3364c55d-09c9-483c-9fe6-7c24f107bd47",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Preexisting Psychiatric Risk Factors and Any and Long-Term Opioid Use in Head and Neck Cancer",
    "abstract": "This cohort study evaluates whether preexisting psychiatric risk factors are associated with any opioid prescriptions and long-term opioid therapy in patients with head and neck cancer.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2649",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2838194",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "118e71d7-6bdb-400d-99a1-533712d0e6f0",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Unilateral vs Bilateral Transoral Surgery for Tonsil SCCa",
    "abstract": "This systematic review and meta-analysis assesses the second primary tumor rates, oncologic survival, functional outcomes, and complications between bilateral and unilateral transoral surgery for tonsillar squamous cell carcinoma (SCCa).",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2235",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2837623",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "93fad5ac-949d-400b-8001-3c51ad75cd7b",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Emerging Role of Pathologic Response in Head and Neck Squamous Cell Carcinoma Immunotherapy",
    "abstract": "Immune checkpoint inhibitors (ICIs) have transformed the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), but combination studies in the definitive disease setting with concurrent chemoradiation have been disappointing. New results from the KEYNOTE-689 phase 3 trial suggest the addition of neoadjuvant followed by adjuvant pembrolizumab in the perioperative setting may represent a new standard of care for resectable locally advanced HNSCC. Pembrolizumab improved event-free survival (EFS) by a median of 21.4 months compared to standard therapy. This trial also established safety in the surgical setting; similar proportions of patients in both the treatment and control arms successfully completed surgery. These findings may transform the treatment landscape of resectable locally advanced HNSCC, where current 3-year progression-free survival remains between 49% and 64%. While the contribution of components, neoadjuvant and/or adjuvant, in KEYNOTE-689 remains undefined, identifying which patients are most likely to benefit from ICI therapy in the definitive setting is an important goal.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.2111",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2837004",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "c61d8733-0ef7-40e1-bd42-afd294acfa9a",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab",
    "abstract": "This cohort study sets out to establish a clinically significant pathologic treatment effect threshold to define pathologic responders and assess related survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC) undergoing neoadjuvant treatment with immune checkpoint inhibitors.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.1707",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2837002",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "d998110b-bafb-4d19-9571-8666d8fb555b",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Patients With Head and Neck Cancer and High Health Care Costs",
    "abstract": "This population-based, retrospective cohort study characterizes patients with head and neck cancer whose care was associated with the highest health care costs during their first year after diagnosis compared with patients with low or medium care costs.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.1976",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2836569",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "712f3b7e-0074-4df2-8249-2f53435a246d",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Unilateral vs Bilateral Transoral Robotic Surgery for HPV-Positive Tonsillar Squamous Cell Carcinoma",
    "abstract": "This cohort study assesses postoperative complications, functional outcomes, contralateral tonsil second primary rates, and survival between unilateral and bilateral transoral robotic surgery for tonsillar human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.1833",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2836483",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "1d92c1d5-c613-4d49-8bf1-de7145c1846d",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Considerations and Cautions in Postoperative Circulating Tumor HPV DNA Kinetics",
    "abstract": "Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) is a rapidly evolving field in which HPV circulating tumor  DNA (ctDNA) has emerged as a promising biomarker for cancer response and minimal residual disease (MRD) detection. In a study published in JAMA Otolaryngology-Head &amp; Neck Surgery, Yin et al investigate the kinetics of postoperative HPV ctDNA in a cohort of patients undergoing primary surgery for HPV-OPSCC. In this prospective study of 84 patients, 57 (82.6%) had detectable pretreatment samples. Of those, 35 patients had blood draws at both specified time points: postoperative day (POD) 1 to 2 and postoperative week (POW) 2. Similar to previous studies, these data support a correlation between preoperative HPV ctDNA levels and tumor stage, size of nodal disease, and presence of extranodal extension. The crux of this recent work, however, focuses on the positive and negative predictive values in addition to specific timing considerations of postoperative circulating tumor DNA detectability. Of 35 patients with complete blood draws, 16 (45.7%) remained detectable at POD 1 to 2; however of these, only 3 continued to be detectable at POW 2. These data yield a negative predictive value of 95% (95% CI, 74%-100%) and a positive predictive value of 19% (95% CI, 4%-46%), highlighting the superior reliability of the 2-week time point for MRD assessment. The authors propose an algorithm whereby patients with detectable samples on POD 1 to 2 undergo repeat testing at POW 2 if being used to guide adjuvant decisions. This 2-step approach balances timely risk stratification with avoidance of overtreatment, recognizing that adjuvant therapy planning requires a lead time of up to 6 weeks for multidisciplinary coordination. Of note, use of MRD for adjuvant decisions is currently restricted to clinical trials as this is not yet standard of care.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.1612",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2834216",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "81932b01-2da3-476c-aebd-1dfc4b80e311",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer",
    "abstract": "This cohort study investigates the early postoperative kinetics of circulating tumor human papillomavirus DNA (ctHPVDNA) in patients with HPV-associated oropharyngeal squamous cell carcinoma.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.1606",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2834215",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "4b5af87d-dc7a-4736-b31a-9c0bcef55eec",
    "source_feed": "https://jamanetwork.com/rss/site_18/74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Current Issue",
    "title": "Efficacy of a Brief Cognitive Behavioral Treatment Across Body Image Distress Domains",
    "abstract": "This secondary analysis of a randomized clinical trial evaluates whether a brief, tailored cognitive behavioral treatment program is effective across multiple domains of head and neck cancer–related body image distress.",
    "published": "Mon, 01 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.0965",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2833816",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "prism_endingpage",
      "prism_number",
      "prism_startingpage",
      "prism_volume",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "f29fefc5-4893-4589-9d73-60c5195347fe",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Pathologic Response and Survival After Neoadjuvant Immunotherapy for HNSCC",
    "abstract": "This systematic review and meta-analysis assesses the association between achievement of a pathologic treatment response and improvement in disease-free survival in head and neck squamous cell carcinoma (HNSCC).",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4573",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842514",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "05899dec-5689-452b-a35d-f9d43bc6b802",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma",
    "abstract": "This cohort study examines recurrence and survival outcomes in propensity-matched thyroid lobectomy vs total thyroidectomy + radioactive iodine patients who presented with ipsilateral N1b papillary thyroid carcinoma.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4653",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842513",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "225de774-4dd9-4212-8e48-f6eff117b6c7",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Pembrolizumab in Head and Neck Cancer—Promise and Price",
    "abstract": "This Viewpoint considers the financial impact of expanding the indication of pembrolizumab for treatment of resectable locally advanced head and neck squamous cell carcinoma expressing programmed cell death 1 ligand 1.",
    "published": "Thu, 18 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4624",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842512",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "d1f7c91b-1b47-4a94-9512-8251c6b1e560",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Hoarseness With Supraglottic Ulcer in an Immunocompetent Adult",
    "abstract": "A 61-year-old man presented to the otolaryngology clinic with a 2-month history of progressive hoarseness, dysphagia, odynophagia, and persistent globus sensation. What is your diagnosis?",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4544",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842393",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "5e6a1156-7967-47be-8275-5d4124e40ce4",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Biofeedback vs Respiratory Retraining for Inducible Laryngeal Obstruction",
    "abstract": "This randomized clinical trial evaluates the effectiveness of video biofeedback compared with respiratory retraining therapy in the treatment of episodic, inhalational dyspnea attributed to inducible laryngeal obstruction.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4542",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842392",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  },
  {
    "id": "07fa58e6-cc1e-47bb-948a-b6722f7ec6ae",
    "source_feed": "https://jamanetwork.com/rss/site_18/onlineFirst_74.xml",
    "journal": "JAMA Otolaryngology–Head & Neck Surgery Online First",
    "title": "Factors Associated With Opioid Refills After Otolaryngology–Head and Neck Surgery",
    "abstract": "This cohort study examines perioperative risk factors associated with opioid refill prescriptions within 90 days after discharge among adults patients who underwent otolaryngology–head and neck surgery procedures.",
    "published": "Thu, 11 Dec 2025 00:00:00 GMT",
    "authors": [],
    "doi": "10.1001/jamaoto.2025.4576",
    "link": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2842391",
    "raw_entry_keys": [
      "guidislink",
      "id",
      "link",
      "links",
      "prism_doi",
      "published",
      "published_parsed",
      "summary",
      "summary_detail",
      "title",
      "title_detail"
    ]
  }
]